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  Abstract 
PATERNAL DIET AND EXERCISE EPIGENETICALLY PROGRAM ENERGY 
EXPENDITURE AND GLUCOSE METABOLISM IN MOUSE OFFSPRING (Under the 
direction of Dr. Alexander K. Murashov) Department of Physiology, August 2013. 
 
 It is currently estimated that a third of Americans suffer from metabolic syndrome, which 
is an obesogenic disease shown to increase risk for developing type 2 diabetes (T2DM) by five-
fold (Diabetes Care, 2012).  The pervasiveness of obesity and T2DM is largely the result of 
unbalanced nutrition and lack of physical activity.  Epidemiological investigations are now 
finding the detrimental effects of poor lifestyle choices, such as consuming a high-fat diet, have 
heritable consequences that persist transgenerationally by way of epigenetic modifications.   
 The epigenome is yet another tier of genetic regulation, one that is capable of producing 
heritable changes in gene expression without altering the underlying sequence of nucleotides.  In 
an effort to better understand the pathogenesis of these overly prevalent diseases (i.e. obesity and 
T2DM) researchers have now set their sights on faulty epigenetic machinery.  To date, research 
has primarily focused on epigenetic modifications associated with maternal descent, mainly 
because of the significant influence had by lifestyle and the environment during 9-months in 
utero.  Consequently, the roles of paternal lifestyle choices, like diet and activity, have not 
received adequate attention.  
 Using a C57BL/6J mouse model we examined the transgenerational effects of a paternal 
high fat-diet and prolonged exercise on male offspring’s susceptibility to glucose intolerance.  
Founder fathers (F0) were randomly divided into three groups: control-diet fathers (CF) // high-
fat fathers (FF); 60% of energy derived from fat // control-diet fathers with exercise wheel (EF).  
After 12 weeks of a high-fat diet (HFD) or free-wheel running F0 males from each group were 
mated with control females. At 4 weeks of age their male offspring (F1) were assigned to either a 
 HFD or control diet (CD) for a duration of 12 weeks.  Metabolic profiles were assessed via 
indirect calorimetry (i.e. metabolic cages), glucose tolerance testing (GTT), fasting plasma 
insulin, eMRI imaging (fat/lean body composition), as well as monitoring of developmental 
milestones.  A comparison between cohorts of offspring on post-natal day 7 revealed a 
significantly lower mean birth weight in the HFD-father offspring (FFO); a factor shown in 
humans to be predictive of obesity and impaired glucose tolerance in adulthood (Bhargava et. al. 
2004).  Additionally, when challenged with a HFD only exercise father offspring (EFO) 
exhibited diabetic traits, such as fasting hyperglycemia, fasting hyperinsulinemia, lower energy 
expenditure, as well as increased body weight and adiposity.   
 To better understand the molecular mechanisms driving these observations quantitative 
real-time PCR was utilized to examine the methylation profile and gene expression within 
insulin sensitive tissues like the liver, pancreas, and gastrocnemius muscle.  Data show intriguing 
differences in expression of several metabolic genes such as: Ogt, Oga, Pdk4, Glut4, Ptpn1, Igf2, 
H19, and FoxO1.  Furthermore, with the exception of Glut4, methylation patterns in fathers were 
preserved within male offspring. These novel findings suggest that offspring have a phenotype 
that is epigenetically programmed to thrive under the same experimental conditions as their 
respective fathers.   
   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 PATERNAL DIET AND EXERCISE EPIGENETICALLY PROGRAM ENERGY 
EXPENDITURE AND GLUCOSE METABOLISM IN MOUSE OFFSPRING 
 
 
 
A Thesis 
Presented To the Faculty of the Department of Physiology 
East Carolina University 
 
 
 
 
In Partial Fulfillment of the Requirements for the Degree 
Master of Science in Biomedical Science 
 
 
 
by 
Michael K. Koury 
August 2013 
 
 
 
 PATERNAL DIET AND EXERCISE EPIGENETICALLY PROGRAM ENERGY 
EXPENDITURE AND GLUCOSE METABOLISM IN MOUSE OFFSPRING 
 
 
 
 
by 
 
Michael K. Koury 
 
 
 
 
 
 
 
DIRECTOR OF THESIS:          __________________________________________________ 
                  Alexander K. Murashov, M.D., Ph.D.  
 
 
COMMITTEE MEMBER:      __________________________________________________  
                P. Darrell Neufer, Ph.D.  
 
 
COMMITTEE MEMBER:         __________________________________________________ 
                            Richard A. Franklin, Ph.D.  
 
 
COMMITTEE MEMBER:        ___________________________________________________ 
                           Dianne Walters, Ph.D. 
 
CHAIR OF THE DEPARTMENT               
OF PHYSIOLOGY:                   ___________________________________________________ 
                           Robert Lust, Ph.D.  
 
DEAN OF THE  
GRADUATE SCHOOL:           ___________________________________________________ 
                          Paul J. Gemperline, Ph.D. 
 Acknowledgements 
I want to first express my deepest gratitude to my thesis director and mentor, Dr. 
Alexander Murashov, for encouraging and facilitating all of my research endeavors. Without his 
guidance, support, and expertise, this project never would have been possible.  
I would also like to thank the other members of my thesis committee, Dr. Darrell Neufer, 
Dr. Dianne Walters, and Dr. Richard Franklin, for all of their helpful advice and wisdom along 
the way. They always made themselves available to provide valuable and constructive feedback - 
for that I am grateful. 
Elena Pak played an invaluable role in the quality and scope of my education. I am 
indebted to her for being so patient during the time spent teaching me several different 
proteomics assays, which were not only cornerstone to completing this study but they are also 
skills I can use in my future endeavors to better clinical medicine through research. 
I want to thank all of the other faculty at the Brody School of Medicine as well whose 
contributions made this research possible. In addition to Dr. Dianne Walters, Dr. Jamie DeWitt 
and Dr. Kevin O'Brien were also kind enough to lend their advice on data analysis. Dr. Brian 
Shewchuk's help was indispensable to my education in primer design and methods for epigenetic 
analyses. 
Finally, I want to thank all of the administrative personnel working in the Department of 
Physiology, as well as those in other supporting departments, for creating such a supportive and 
friendly learning environment. 
Last, but certainly not least, I want to sincerely thank my friends, my family, and 
especially my wife Emily, for being so understanding and supportive during my academic 
pursuit to earn a Masters in Biomedical Sciences.   
 Table of Contents 
 
List of Figures----------------------------------------------------------------------------------------------- XI 
List of Tables-----------------------------------------------------------------------------------------------XIV 
List of Abbreviations---------------------------------------------------------------------------------------XV 
1.0    Introduction----------------------------------------------------------------------------------------------1 
       1.1     Importance of Study  ------------------------------------------------------------------------1   
       1.2     Statement of Problem -----------------------------------------------------------------------2 
             1.3     Specific Aims---------------------------------------------------------------------------------2 
2.0     Literature Review  -------------------------------------------------------------------------------------5 
     2.1    Epigenetics: Bridging the Gap between Diet and Genetics  ---------------------------5 
  2.2   The Etiology of Metabolic Syndrome   ---------------------------------------------------6 
 2.3     The Tissue Specific Pathology of Glucose Impairment  -------------------------------7 
     2.3.1    Pancreas   -------------------------------------------------------------------8 
     2.3.2    Liver   -----------------------------------------------------------------------8 
     2.3.3    Skeletal Muscle  -----------------------------------------------------------9 
   2.4     Molecular Mechanisms Implicated in Glucose Impairment -------------------------10 
  2.4.1     CpG Methylation --------------------------------------------------------10 
  2.4.2     Chromatin and histone modification  ---------------------------------12 
  2.4.3 Evidence of transgenerational glucose impairment   ---------------15 
  2.4.4 H19 & Igf2 Cis acting regulation -------------------------------------17 
  2.4.5 Glucose homeostasis by Pdk4 -----------------------------------------20 
  2.4.6 Hepatic glucose release by FoxO1  -----------------------------------20 
   2.4.7 Ptpn1: Insulin signaling antagonist    ---------------------------------21 
   2.4.8 Slc2A4 (GLUT4): Glucose sensitivity  -------------------------------22 
2.5 O-GlcNAc: The Chief Nutrient Sensor  ------------------------------------------------24 
 2.5.1 What makes O-GlcNAc so different? --------------------------------24 
 2.5.2      Detecting the elusive β-O-GlcNAc------------------------------------25 
 2.5.3  Overview of O-GlcNAc cycling---------------------------------------26 
 2.5.4  Dynamic interactions with protein phosphorylation  ---------------27 
          2.5.5      O-GlcNAc cycling enzymes -------------------------------------------27 
2.5.5.1 O-GlcNAc Transferase  -----------------------------------28 
2.5.5.2      O-GlcNAcase-----------------------------------------------30 
             2.5.6 A Word on epigenetic regulation by O-GlcNAc --------------------31 
3.0 Materials and Methods -----------------------------------------------------------------------------33 
   3.1 Approach -----------------------------------------------------------------------------------33 
   3.2  Housing Conditions and Diet ------------------------------------------------------------34 
   3.3 Wheel Cages and Exercise ---------------------------------------------------------------34 
 3.4  Developmental Monitoring --------------------------------------------------------------35 
 3.5  Weight and Adiposity Measurements --------------------------------------------------35 
 3.6 Metabolic Profiling -----------------------------------------------------------------------35 
  3.7 Glucose Tolerance Testing and Plasma Insulin ---------------------------------------36 
3.8 Tissue Collection and Processing -------------------------------------------------------37 
3.9 Protein Extraction and Downstream Processing --------------------------------------38 
            3.9.1       Western Blot Analysis --------------------------------------------------38 
3.10 RNA Isolation and Downstream Processing  ------------------------------------------40 
 3.10.1 Semi-quantitative Real-Time PCR: cDNA---------------------------41 
3.11  DNA Isolation and Downstream Processing-------------------------------------------41 
3.11.1 Sonication and Agarose Gel Electrophoresis ------------------------42 
3.11.2     Methylation Capture ----------------------------------------------------44 
3.11.3     Semi-Quantitative Real-Time PCR: Genomic DNA ---------------45 
3.12 Primer Design and Optimization -----------------------------------------------------------------46 
3.13 Statistical Analysis ---------------------------------------------------------------------------------48 
4.0      Presentation of Findings----------------------------------------------------------------------------49 
4.1 Body Weight and Adiposity -------------------------------------------------------------49 
            4.2 Metabolic Profiling   ----------------------------------------------------------------------52 
          4.2.1 Energy Expenditure -----------------------------------------------------52 
  4.2.2 Activity -------------------------------------------------------------------55 
     4.2.3 Food and Water Consumption  ----------------------------------------57 
            4.3 Glucose Tolerance Test and Plasma Insulin -------------------------------------------60 
            4.4 Developmental Monitoring---------------------------------------------------------------63 
  4.5  F0 Protein Expression ---------------------------------------------------------------------65 
4.6 Gene Expression  --------------------------------------------------------------------------67 
 4.6.1 Skeletal Muscle mRNA-------------------------------------------------67 
 4.6.2 Pancreatic mRNA--------------------------------------------------------73 
 4.6.3 Hepatic mRNA-----------------------------------------------------------78 
4.7 Methylation Analysis ---------------------------------------------------------------------82 
  4.7.1 Muscle---------------------------------------------------------------------82 
 4.7.2 Pancreas-------------------------------------------------------------------87 
  4.7.3 Liver  ----------------------------------------------------------------------91 
5.0  Discussion -------------------------------------------------------------------------------------------96 
Acknowledgement -----------------------------------------------------------------------------------------101 
References --------------------------------------------------------------------------------------------------102 
Appendix ---------------------------------------------------------------------------------------------------114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 List of Figures 
 
Figure 1------------------------------------------------------------------------------------------------3 
Figure 2----------------------------------------------------------------------------------------------14 
Figure 3----------------------------------------------------------------------------------------------19 
Figure 4----------------------------------------------------------------------------------------------23 
Figure 5----------------------------------------------------------------------------------------------32 
Figure 6----------------------------------------------------------------------------------------------33 
Figure 7----------------------------------------------------------------------------------------------43 
Figure 8----------------------------------------------------------------------------------------------50 
Figure 9----------------------------------------------------------------------------------------------51 
Figure 10---------------------------------------------------------------------------------------------54 
Figure 11---------------------------------------------------------------------------------------------56 
Figure 12---------------------------------------------------------------------------------------------58 
Figure 13---------------------------------------------------------------------------------------------59 
Figure 14---------------------------------------------------------------------------------------------59 
Figure 15---------------------------------------------------------------------------------------------61 
Figure 16---------------------------------------------------------------------------------------------62 
Figure 17---------------------------------------------------------------------------------------------64 
Figure 18---------------------------------------------------------------------------------------------66 
Figure 19---------------------------------------------------------------------------------------------68 
Figure 20---------------------------------------------------------------------------------------------69 
XII 
Figure 21---------------------------------------------------------------------------------------------70 
Figure 22---------------------------------------------------------------------------------------------72 
Figure 23---------------------------------------------------------------------------------------------72 
Figure 24---------------------------------------------------------------------------------------------73 
Figure 25---------------------------------------------------------------------------------------------74 
Figure 26---------------------------------------------------------------------------------------------76 
Figure 27---------------------------------------------------------------------------------------------76 
Figure 28---------------------------------------------------------------------------------------------77 
Figure 29---------------------------------------------------------------------------------------------77 
Figure 30---------------------------------------------------------------------------------------------78 
Figure 31---------------------------------------------------------------------------------------------79 
Figure 32---------------------------------------------------------------------------------------------80 
Figure 33---------------------------------------------------------------------------------------------81 
Figure 34---------------------------------------------------------------------------------------------81 
Figure 35---------------------------------------------------------------------------------------------84 
Figure 36---------------------------------------------------------------------------------------------84 
Figure 37---------------------------------------------------------------------------------------------85 
Figure 38---------------------------------------------------------------------------------------------85 
Figure 39---------------------------------------------------------------------------------------------86 
Figure 40---------------------------------------------------------------------------------------------86 
Figure 41---------------------------------------------------------------------------------------------87 
Figure 42---------------------------------------------------------------------------------------------88 
Figure 43---------------------------------------------------------------------------------------------89 
XIII 
Figure 44---------------------------------------------------------------------------------------------90 
Figure 45---------------------------------------------------------------------------------------------90 
Figure 46---------------------------------------------------------------------------------------------91 
Figure 47---------------------------------------------------------------------------------------------91 
Figure 48---------------------------------------------------------------------------------------------93 
Figure 49---------------------------------------------------------------------------------------------93 
Figure 50---------------------------------------------------------------------------------------------95 
Figure 51---------------------------------------------------------------------------------------------95 
 
 
 List of Tables 
 
Table 1-------------------------------------------------------------------------------------------------4 
Table 2-----------------------------------------------------------------------------------------------47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 List of Abbreviations 
 
NTC --------------------No Template Control 
5’ ICDMR -------------5 Prime Imprint Control Differentially Methylated Region 
AKT --------------------Protein Kinase B 
BSA -------------------- Bovine Serum Albumin  
CARM1 --------------- Coactivator-associated arginine methyltransferase 1 
CF ---------------------- Control Father 
CFO -------------------- Control Father Offspring 
DEPC ------------------ Diethyl pyrocarbonate 
dH2O ------------------- Distilled Water 
DMR ------------------- Differentially Methylated Region 
DNA ------------------- Deoxyribonucleic Acid 
EDTA ------------------Ethylenediaminetetraacetic acid 
EF ---------------------- Exercise Father 
EFO -------------------- Exercise Father Offspring  
eNOS ------------------ Endothelial Nitric Oxide Synthase 
ER ---------------------- Endoplasmic Reticulum  
EtBr -------------------- Ethidium Bromide 
FF ---------------------- Fat Father (high-fat diet) 
FFO -------------------- Fat Father Offspring  
FoxO1 ----------------- Forkhead box class O 1 
 GFAT ------------------D-fructose-6-phosphate amidotransferase 1
XVI 
GFPT1 -----------------Glucose-fructose phosphatase 1 
Glut4 -------------------Glucose transporter type 4 
GTT --------------------Glucose Tolerance Test 
HAT Domain --------- Histone Acetyltransferase domain 
HBP --------------------Hexosamine Biosynthetic pathway 
HCF1 -------------------Host Cell Factor 1 
Ins2 ---------------------Insulin II 
IRS1 --------------------Insulin receptor substrate-1 
MALDI-TOF ---------Matrix-assisted laser desorption time-of-flight 
MBD-cap --------------Methyl-Binding Domain Capture 
MBD2  -----------------Methyl-CpG Binding Domain Protein 2 
Mgea5  -----------------Meningioma-expressed antigen 5 
MLL5 ------------------Mixed-linease leukemia 5 (MLL5),  
mOGT ------------------Mitochondria-OGT 
ncOGA -----------------Nucleocytoplasmic-OGA 
ncOGT -----------------Nucleocytoplasmic-OGT 
NeuroD1 ---------------Neurogenic differentiation 1 
NFB -------------------Nuclear factor kappa-light-chain-enhancer of activated B cells 
nOGA ------------------Nuclear OGA 
O-GlcNAc -------------Beta-linked-ortho-acetylglucosamine 
Oga ---------------------Peptide O-GlcNAc-beta-N-acetylglucosaminidase 
Ogt----------------------Uridine diphospho-N-acetylglucosamine:peptide β-N                 k                                       
k                                   acetylglucosaminyltransferase or O-GlcNAc Transferase 
 
XVII 
PBS ---------------------Phosphate buffered saline 
PBST -------------------Phosphate buffered saline-tween 
PcG ---------------------Polycomb Group 
PCG-1α-----------------Peroxisome proliferator-activated receptor gamma coactivator  1-
a                                   alpha 
PCR ---------------------Polymerase chain reaction 
PDC ---------------------Pyruvate dehydrogenase complex 
PDK4 -------------------Pyruvate dehydrogenase lipoamide kinase isozyme 4  
PDX-1 ------------------Pancreatic and duodenal homeobox 1 
PMSF -------------------Phenylmethanesulfonyl fluoride 
PP1c --------------------Protein phosphatase 1 
Ptpn1 -------------------Tyrosine-protein phosphatase non-receptor type 1 
PVDF ------------------ Polyvinylidene difluoride 
RIPA Buffer -----------Radioimmunoprecipitation assay 
RNA --------------------Ribonucleic acid 
ROS ---------------------Reactive oxygenated species 
SDS ---------------------Sodium dodecyl sulfate 
SNP ---------------------Single Nucleotide Polymorphism 
sOGT -------------------Short OGT 
Sxc ----------------------Super sex combs  
T2DM ------------------Type 2 Diabetes Mellitus 
TBE ---------------------Tris-borate-EDTA 
TBS ---------------------Tris buffered saline 
TBST -------------------Tris buffered saline-tween 
XVIII 
TPR ---------------------Tetratricopeptide repeat 
TSS----------------------Transcriptional start site 
UDP-GlcNAc ---------Uridine diphosphate N-acetylglucosamine 
XCI ---------------------X-Chromosome Inactivation  
 1.0  Introduction 
 
1.1  Importance of Study 
 The United States has become one of the most overfed, yet undernourished, nations in the 
world with an estimated two-thirds of adults now considered to be over-weight (BMI≥25) and 
approximately 35.7% obese (BMI≥30) [1].  In addition to the staggering rates of obesity observed 
in the adult population, over the last 30 years its prevalence among children and adolescents 
(aged 2-19) has more than tripled (Figure 1) [
2
].  The pervasiveness of obesity, both in children 
and adults, largely stems from consuming a high calorie diet while living a sedentary lifestyle [
3
].  
A proper balance between dietary intake and energy expenditure is crucial not only for 
maintaining a healthy weight but also for preserving normal glucose metabolism.   
 The onset of obesity has been shown to usher in an array of other metabolic dysfunctions 
such as Type II Diabetes Mellitus (T2DM), a disease which currently affects more than 25 
million people in the United States and is seen to occur five- to six- times more often among 
obese individuals [
4
].  These two ailments alone have placed an enormous burden on the Nation’s 
health care system, and in 2012 were found to account for nearly $366 billion in total medical 
costs [
5-7
].  In an effort to combat this ongoing obesity epidemic, and the co-morbidities 
inextricably tied to it, researchers have begun exploring new avenues of intervention within the 
developing field of epigenetics. 
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1.2  Statement of Problem 
 While both genetic and non-genetic environmental factors are known to contribute to the 
heritability of obesity and type II diabetes mellitus (T2DM), a change within the population gene 
pool during the past three decades doesn’t account for such a rapid increase in the prevalence of 
obesity and diabetes in children [
8
].  Instead, such changes are likely a product of epigenetic 
modifications, which alter genomic transcription in a manner that affects the metabolic 
phenotype of successive generations [
8
].  Previous studies, which largely focused on epigenetic 
factors of maternal descent, successfully established there to be a link between maternal 
metabolism and that of their offspring [
9,10
].  However, paternal influences on the next generation 
are still poorly understood.  Therefore, the following study used a mouse model to explore how 
paternal diet and exercise can epigenetically program the metabolism of male progeny.   
 
1.3  Specific Aims 
1)  Evaluate differences between the metabolic profiles of male offspring born to fathers that 
consumed a HFD or to fathers given free access to an exercise wheel. Comparative analysis will 
be performed on data obtained by indirect calorimetry, glucose tolerance testing, magnetic 
resonance imaging, as well as measures of plasma insulin. 
 
2)  Identify any disparities in the gene expression or methylation profile between offspring 
cohorts (F1 males) that are attributable to paternal exercise or paternal consumption of a HFD. 
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Figure 1.   A – Number of newly diagnosed cases of T2DM in the United States.  B – 
Correlation between increases in obesity and T2DM 
 
Age-Adjusted Prevalence of  Obesity and Diagnosed Diabetes 
Among U.S. Adults Aged 18 Years or older 
Obesity (BMI ≥30 kg/m2) 
Diabetes 
1994 
1994 
2000 
2000 
      No Data         <14.0%         14.0-17.9%         18.0-21.9%          22.0-25.9%           >26.0% 
      No Data          <4.5%           4.5-5.9%             6.0-7.4%             7.5-8.9%               >9.0% 
CDC’s Division of  Diabetes Translation. National Diabetes Surveillance System available at http://
www.cdc.gov/diabetes/statistics 
2010 
2010 
A 
B 
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    Overweight or Obese  
(BMI ≥ 85th percentile) 
                Obesity  
(BMI ≥ 95th percentile) 
All 31.8% 16.9% 
2-5 year olds 26.7% 12.1% 
6-11 year olds 32.6% 18.0% 
12-19 year olds 33.6% 18.4% 
 
Table 1.  U.S. Prevalence of Childhood Overweight and Obesity (NHANES 2009-2010) 
 
 
 
 
 
 
 
 
Data Reproduced from: Ogden, C. L., Carroll, M. D., Kit, B.K., & Flegal, K. M. (2012). 
Prevalence of obesity and trends in body mass index among U.S. children and adolescents, 
1999-2010. Journal of the American Medical Association, 307(5), 483-490 
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2.0  Literature Review 
 
2.1  Epigenetics: Bridging the Gap between Diet and Genetics 
The term ‘epigenetics’ was first coined in the 1940s by developmental biologist Conrad 
Waddington who defined it as “the interactions of genes with their environment, which bring the 
phenotype into being” [11].  However, over the past seven decades Waddington’s description has 
slowly evolved into the modern definition, which characterizes epigenetics as being heritable 
changes in gene expression that occur without any underlying change in the gene sequence [
12
].  
The epigenome is a complex stratum of environmentally regulated mechanisms, capable 
of producing rapid and enduring changes in genomic activity.  Such changes in the genome are 
potentially transgenerational, and primarily occur through histone modification, chromatin 
remodeling, and DNA methylation [
13-16
].  
 Environmental factors such as a sedentary lifestyle or having poor dietary habits (i.e. 
high in calories), are known for their catalytic role in the transgenerational etiology of Type 2 
Diabetes (T2DM) [
17-19
].  Although the exact mechanisms are not yet fully understood T2DM is 
thought to influence epigenetic programming within the germ line, which can have deleterious 
effects that persist for several generations [
15,17,18,20
]. 
In addition to T2DM, to date investigators have identified a broad spectrum of 
pathologies thought to be directly associated with abnormal epigenetic programming.  Other 
diseases found to exhibit unusual epigenetic profiles include the methylation patterns observed in 
cancerous tissues [
21
].  The genes residing in a metastatic tumor are typically found to be in a 
hypomethylated state. The tumor suppressor genes within these cancerous cells, however, are 
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primarily found to be hypermethylated [
21
].  Furthermore, epigenetic dysfunction has been 
implicated in the etiology of multiple diseases through its involvement in fetal programming. 
That is, if deregulated epigenetic modifications occur during embryonic development the 
changes made are often permanent, and consequently affect the susceptibility for certain 
individuals to contract diseases later on in adulthood [
22
].  The growing body of evidence linking 
dysfunctional epigenetic mechanisms to the etiology of complex metabolic diseases is 
compelling, and one day soon may offer clinical benefits in the form of novel drug developments 
as well as predictive biomarkers.  
 
2.2  The Etiology of Metabolic Syndrome 
It was nearly a century ago that pioneers working in the field of medical sciences first 
described the convoluted signs of a metabolic-like syndrome, which they recognized after 
observing an incoincidental coexistence of diseases.  Since that time names such as ‘syndrome 
X’, ‘insulin resistance syndrome’, and ‘metabolic syndrome’ have been used interchangeably for 
describing a condition that, until recently, lacked any constitutive guidelines of classification 
[
16,23,24
].  Over the past decade, however, the term ‘metabolic syndrome’ has finally gathered 
enough traction to evolve from an ambiguous idiom into a well-defined medical syndrome; one 
that is estimated to affect nearly 25% of the adults in America [
25
]. 
Although several risk factors are used for the purpose of making a clinical diagnosis of 
metabolic syndrome, apart from diet and exercise there still are no suitable treatments available. 
Efforts to develop pharmacological therapies have proven to be difficult, primarily because no 
unified origin has been found to account for the pathogenesis of metabolic syndrome.  Currently, 
mandates established by the World Health Organization (WHO), the American Association of 
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Clinical Endocrinologists (AACE), and the National Cholesterol Education Program Adult 
Treatment Panel II (NCEP ATP III) are used for diagnosing metabolic syndrome [
26,27
].  
Although in most respects they are the same, the WHOs slightly more stringent criterion are 
more commonly used in clinical settings [
26
].  This model dictates that patients must present with 
fasting hyperglycemia or hyperinsulinemia in addition to exhibiting at least two of the following 
risk factors: centralized obesity (BMI ≥ 30), fasting hyperlipidemia (triglycerides ≥ 150 mg/dl), 
chronic hypertension (blood pressure ≥ 130/85 mm Hg), below average high density lipoprotein 
cholesterol (HDL ≤ 40 and 50 mg/dl for men and women respectively), or microalbuminuria [26].  
Those who suffer from three or more of these comorbidities are on the precipice of developing 
diseases like type II diabetes mellitus (T2DM) or cardiovascular disease (CVD), both of which 
are maladies known to catalyze a kaleidoscopic array of other dysfunctions [
26
].  The following 
sections will serve to elaborate on glucose and insulin metabolism, which are cornerstone 
elements that often trigger or potentiate the other comorbidities listed. 
 
2.3  The Tissue Specific Pathology of Glucose Impairment  
Glucose is the primary source of energy used by the human body and is therefore, to no 
surprise, tightly regulated by a myriad of homeostatic mechanisms.  Typically, the fasting 
glucose concentration for a euglycemic individual ranges between 70-100 mg/dl, whereas those 
who suffer from T2DM exhibit values in excess of 126 mg/dl [
28
].  Hyperinsulinemia is often 
seen to occur concomitantly to hyperglycemia, and together they serve as the hallmark traits for a 
T2DM phenotype [
29
].  Unfortunately, their clinical manifestations only become apparent long 
after their pathogenic mechanisms have been at work.  It is now widely accepted that impaired 
glucose and insulin signaling are concordant pathologies, their origins of dysfunctions, however, 
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are still under debate.  Current evidence has implicated the pathology to result from a set of 
complex dysfunctions, which occurs in several metabolic tissues like the pancreas, the liver, and 
the muscle [
4,16,24,29-32
].  
2.3.1  Pancreas  
  The pancreas has been linked to the pathology of type 2 diabetes for a multitude of 
reasons.  The endocrine function of pancreatic tissue, specifically the beta cells of the Islets of 
Langerhans, are responsible for secreting the hormone insulin to counteract high concentrations 
of peripheral glucose [
29
].  However, in T2DM the insulin producing beta cells are unable to keep 
up with the demand imposed by a hyperglycemic state [
29
].  As a result of the pancreatic beta 
cells working over-time a hyperinsulinemic state manifests that ultimately facilitates the onset of 
insulin resistance, which is a condition characterized by the inability of peripheral tissues (e.g. 
muscle, liver, adipose) to respond to insulin [
29
].  After prolonged and unsuccessful efforts to 
produce an adequate supply of insulin the pancreas begins to suffer from the toxic effects of 
chronic hyperglycemia [
33
].  This glucose-induced damage to beta cells further impairs the 
pancreas’s ability to produce sufficient levels of insulin, which both exacerbates and perpetuates 
metabolic dysfunction [
33
]. 
2.3.2  Liver  
The liver is situated at a key juncture point where all nutrient intake and insulin are first 
passed through its hepatocellular network prior to entering systemic circulation.  It is theorized 
that obesity is a leading contributor in the development of insulin resistance, a pathology that 
subsequently promotes hepatic hyperglycemia [
34
].  In addition to excessive blood glucose, 
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dyslipidemia is also seen to occur in the form of elevated triglycerides, elevated free fatty acids 
(FFA) and reduced levels of HDL cholesterol [
35
]. 
Liver disease is one of the most common causes of death associated with T2DM [
30
].  In 
fact, virtually every subset of liver dysfunction is found to occur more often in diabetic patients 
including such pathologies as hepatocellular carcinoma, nonalcoholic fatty liver disease, 
cirrhosis, abnormal liver enzymes, and acute liver failure [
30,31
].  Based on these criteria T2DM 
clearly is not a disease only associated with hyperglycemia and insulin resistance.   
Until recently it was thought that hepatic glucose production (HGP) was at the heart of 
fasting hyperglycemia [
36
]. However, research efforts have proven this theory to be false by 
demonstrating basal HGP in T2DM patients closely resembles that of normal euglycemic 
individuals [
31
].  This observation indicates the problem is instead likely to occur during the 
postprandial state, and potentially involves elevated FFA and triglyceride release, which sustains 
the insulin resistant state of peripheral tissues. 
 2.3.3  Skeletal Muscle  
Insulin resistance occurring at the level of the skeletal muscle is a complex defect thought 
to occur years before other clinical manifestations appear [
37
].  Skeletal muscle is the primary site 
of glucose uptake and has been shown to utilize approximately 80-90% of glucose under normal 
euglycemic conditions [
37
].   
Although multitudes of genetic factors have been implicated as causative agents of 
muscular insulin resistance, the broad array of evidence compiled to date would suggest that 
rather than a single culprit it’s more likely to be a combinatorial effect of much deeper 
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complexity.  In the current study, gene expression for several different transcripts were 
examined, all of which are known participants in glucose and insulin homeostasis.    
 
2.4  Molecular Mechanisms Implicated in Glucose Impairment   
As previously stated, researchers have compiled an enormous amount of data to 
substantiate the link suspected to exist between epigenetic programming and Type 2 Diabetes 
[
12,13,38-40
].  These data have shown that an array of different molecular pathways are 
participatory in transgenerational glucose impairment via indirect mechanisms that alter the germ 
line and begin in insulin sensitive tissues like the pancreas, the liver, adipose tissue, as well as 
skeletal muscle [
13,31,37,41
].  
 In an effort to contrive more effective treatments for glucose impairment occurring in 
these tissues it is essential to have a solid understanding of the constitutive elements causing 
dysfunction.  Therefore, the following sections will offer a comprehensive review of the 
mechanisms known to be fundamental in the onset of glucose impairment, as well as those that 
facilitate its transgenerational persistence. 
2.4.1  CpG Methylation  
 The most common form of epigenetic modification studied is DNA methylation, which is 
an event found to occur in all vertebrate animals [
42
].  Methylation is a fairly stable repressive 
marker for gene expression that is characterized by the addition of a methyl group to the 5
th
 
carbon of cytosine’s pyrimidine ring, via the enzymatic actions of methyltransferases [11,18]. 
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 Although DNA methylation is not exclusive to cytosines, and can also be found to occur 
on adenine bases, it is unquestionably most prevalent on repetitive strings of cytosines bound to 
guanine nucleotides (CpG Islands) [
42
].  The acronym ‘CpG’ simply reflects adjacent cytosine 
and guanine nucleotide bases, bound together by a phosphodiester linkage.  The frequency of 
methylated CpG’s that occurs within a defined range of DNA (length > 200bp) is the classifying 
proponent used to distinguish two separate categories of CpG’s termed islands and CpG and 
deserts [
43
].  CpG islands are defined as having a GC content greater than 50%, with an 
observed-to-expected CpG ratio exceeding 60% [
43
].  CpG islands are a prevalent feature of gene 
promoters, especially in humans where high CpG content is found in approximately 70% of all 
promoters [
43
].  This characteristic situates DNA methylation in a prime position to block 
transcriptional initiation complexes, and therefore prevent gene activity. 
 As stated, DNA methylation is an essential factor involved with normal embryonic 
development [
44
].  However, the dynamic sequences of events that occur upon zygote 
fertilization have made elucidating parental specific pathology a challenging task.   It is well 
known that nearly all methylated marks acquired over the lifetime of both parents are wiped 
clean, or hydroxylated, at the time of zygote formation [
45,46
].  Subsequent to erasing the parental 
methylation patterns the epigenetic memory that resides within the maternal lineage is used as a 
template for re-methylating the genome of the developing embryo [
47
].  It is crucial to note 
however that certain genes existing within both paternal and maternal lineages are located in 
protected regions called Imprint Control Regions (ICR) [
47
].  These sequences are shielded from 
de-methylation, and thus are able to reflect a parent specific methylation pattern. 
 Due to the nature of cytosine biosynthesis the level of methylation is highly dependent on 
the availability of several cofactors and micronutrients (e.g. folic acid, choline, etc.) [
48
].  This 
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notion, in combination with the methylation erasure previously described, serve to partially 
illustrate the justification used by those researchers whose investigations are confined to the 
maternal contributions made during 9 months of gestation, which is a time when a nutritional 
diet is sine qua non to embryonic development. 
 
2.4.2  Chromatin and histone modification 
In addition to DNA methylation both chromatin remodeling and histone modifications 
are vital to epigenetic programming [
14,49
].  These names are umbrella terms used to describe, in 
addition to methylation, a myriad of specific mechanisms such as: acetylation, phosphorylation, 
ubiquitylation, sumoylation, biotinylation, and O-GlcNAcylation [
11,49
].     
The human genome packs an unfathomable amount of information into a highly 
organized storage network that is readily accessible at a moments notice.  This feat begins with 
DNAs affinity for a cheese wheel shaped cluster of eight proteins known as a histone, which 
DNA has a natural tendency for wrapping itself around while not in use [
49
].  However, when 
cellular functions demand additional gene transcripts the respective coding sequences are lured 
away from the histone core by proteins possessing an even greater electrostatic attraction for 
DNAs phosphodiester backbone, thereby releasing it from a tightly wrapped and dormant state.  
Upon severing the transient bond formed with epigenetic factors, gene transcription terminates 
and DNA returns to a tightly wrapped state around its designated histone.  At this stage histones 
themselves begin to condense and twist into a packed arrangement forming what are known as 
nucleosomes [
14
].  The condensation process is repeated yet again on the chains of newly formed 
nucleosomes, at which time the structure known as chromatin makes its debut.  Chromatin is the 
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constitutive element for chromosomes, and represents the densest level of DNA compression 
[
14
].  
As was briefly illustrated here epigenetic regulation is a multifactorial process adding 
exponential diversity to genomic regulation, and it can be found to offer both extraordinary 
advantage as well as extraordinary risk.  In many respects epigenetic control promotes a merger 
of Darwinian and Lamarkian evolutionary theories by allowing for immediate adaptation at the 
genomic level.  Contrary to such a benefit, however, are the severe risks presented by any 
dysfunction in activity, which have potential to be maintained for several generations. 
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Figure 2.  Genomic storage and epigenetic modifications 
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2.4.3  Evidence of transgenerational glucose impairment 
 Several recent lines of evidence, collected from both humans and mice, have confirmed 
transgenerational inheritance does occur by route of the paternal germ line [
13,50,51
].  As 
previously mentioned epigenetic changes are the product of environmental exposures, which 
includes toxins and dietary habits alike.  One study performed by Skinner et. al. (2010) painted a 
clear picture on the transgenerational effects had by maternal exposure to the toxin vinclozolin, 
which is an endocrine disruptor found to carry its toxic effects through the paternal lineage, even 
managing to alter promoter methylation patterns within the sperm of F3 rat offspring [
52
]!  While 
another study conducted by Carone et. al. (2010) demonstrated that a low protein diet fed to male 
mice altered the methylation patterns within their offspring (F1), which consequently resulted in 
a dysfunctional lipid metabolism [
38
].  These findings and others have implicated numerous non-
genetic factors, like cytosine methylation and changes in microRNA, as the origin of fetal 
programming because both are capable of shaping the development of soon-to-be fertilized 
zygotes [
53
].   
One investigation by Sheau-Feng Ng, et. al. (2010), using Sprague-Dawley rats, showed 
that a paternal high-fat diet directly contributes to β-cell dysfunction in F1 female offspring [
40
].  
Upon examining the pancreatic tissues of adult female offspring they found expressions for 642 
islet genes to be significantly different than those offspring sired by control fathers (p<0.01).  
Furthermore, a paternal HFD contributed to an overall reduction in total islet area within female 
offspring (-23%; p<0.04) [
40
].  Interestingly the impaired glucose tolerance and insulin secretion 
experienced in F1 females was observed in the absence of obesity or any changes in energy 
metabolism, indicating that metabolic dysfunction was likely the product of an endocrine 
disruption that interfered with pancreatic β-cell function [40].  Although this particular study 
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failed to investigate molecular changes occurring within the father’s sperm they believed it to be 
the likely mode of transmission for which the differentially methylated promoter of Il13ra2 
(hypomethylated; 1.76-fold resulting increase in expression), a gene heavily involved in islet 
development and function, was able to facilitate metabolic impairment in the pancreas of 
offspring.  
The findings made by Sheau-Feng Ng, et. al. have been substantiated by a handful of 
other studies that specifically focused on changes occurring at the level of the sperm.  One such 
example can be seen in a study hosted by Fullston et. al. (2013), which demonstrated that 
paternal HFD was associated with a 25% reduction in DNA methylation within sperm that was 
not only linked to metabolic impairment (e.g. adiposity and insulin resistance) within F1 males 
and females, but was also found to affect offspring metabolism in the F2 generation [
54
].  Dunn 
GA and Bale TL (2011) further showed a maternal HFD reduced insulin sensitivity and 
increased body size in two successive generations of offspring  “via both maternal and paternal 
lineages” [9].  Additional findings gathered in the Newborn Epigenetics Study by Soubry et. al. 
(2013) revealed that in humans (n=79) paternal obesity does in fact reprogram “imprint marks 
during spermatogenesis” [51].  This was seen as severe hypomethylation at the DMR of Igf2, 
which is a trait that also happens to be a known risk factor for several types of malignant cancers 
(e.g. rectal cancer, ovarian cancer etc.) [
51
]. 
Despite the fact that, to date, the vast majority of diet-centered transgenerational research 
has focused on F1 and F2 female progeny, the observations discussed here clearly demonstrate 
paternal diet plays a significant role in epigenetically shaping the metabolic phenotype of male 
offspring.  Results gathered in the current study will hopefully serve to partially fill the void of 
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information that exists on the epigenetic effects had by paternal diet and exercise on male 
offspring within the F1 generation. 
2.4.4  H19 & Igf2 Cis acting regulation  
H19 and Igf2 are imprinted genes that have recently come into the lime light of research 
because of their suspected roles in transgenerational metabolic impairment [
13,51,55-58
].  
Monoallelic expression (i.e. parent-specific) of imprinted genes like H19 and Igf2 is a 
phenomenon that transpires from epigenetic modifications that occur within differentially 
methylated regions (DMR) [
13,59
].  The H19 gene is a maternally inherited allele responsible for 
transcribing a noncoding RNA of unknown function, while insulin-like growth factor 2 (Igf2) is 
a paternally derived allele that encodes an embryonic mitogen responsible for promoting tissue-
specific growth during gestation [
56
].  
The series of mechanisms that regulate Igf2 and H19 genomic imprinting, in addition to 
the genes themselves, are highly conserved from rodents to humans which has allowed them to 
be thoroughly investigated using established mouse models [
55,56
].  Imprinting at Igf2/H19 is 
particularly relevant to the current topic of discussion for two reasons.  First, despite still having 
much to learn about the exact regulatory mechanisms involved, the Igf2/H19 imprinting scheme 
offers a well-characterized example of paternally inherited epigenetic dysfunction [
51,55,58-61
].  
Secondly, it is a paradigm that has been subject to extensive investigation in humans, where 
studies have demonstrated a clinical correlate between hypomethylation and low birth weight, 
which is a trait well-supported as a predictor of adult onset T2DM [
62
].   
The syntenic genes H19 and Igf2, located on human chromosome 11, are separated by an 
intronic sequence that spans roughly ~80 Kb [
59
].  The cis acting regulatory zone shared by H19 
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and Igf2 is located approximately ~2 Kb to ~4 Kb upstream from H19’s transcriptional start site 
(TSS) in a domain referred to here as the 5’ differentially methylated imprint control region (5’ 
DMICR) [
56,60
].  This sequence serves a dual role, one function of which is to bind CTCF 
insulator proteins on the maternal chromosome (CCCTC-binding factor).  It is also particularly 
important to note that in both mice and humans alike these insulating CTCF proteins are 
typically unable to bind on the fathers DMICR, primarily due to the hypermethylated state of 
resident CpGs.  Hypermethylation within this region protects the developing zygote from 
exhibiting biallelic expression for both maternal and paternal H19. (Figure 3) 
The second primary function of the CTCF proteins on the maternal chromosome is to act 
as a barrier that prevents enhancers from binding inside the H19 promoter, thereby allowing 
them to travel further upstream where they instead promote the monoallelic expression of 
paternal Igf2 [
60
].  The transcriptional activity of H19 occurs on the maternal chromosome where 
the DMIC region its self serves as the docking site for the enhancers described above, all four of 
which are located ~10 kb downstream from H19’s TSS [60].  Irregular methylation occurring at 
the DMICR affects the transcription of both H19 and Igf2, an occurrence recently identified to be 
a potential contributor to impaired islet function within offspring [
13
]. 
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Figure 3.  Cis-acting regulation of H19 and Igf2. 
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2.4.5  Glucose homeostasis by Pdk4 
The pyruvate dehydrogenase complex (PDC) plays a pivotal role in the metabolic state of 
pancreatic islets, the liver, and also the muscle [
63,64
]. PDC is responsible for glucose oxidation 
(i.e. breakdown).  Its level of activity, however, is primarily dependent on the negative regulation 
imposed by pyruvate dehydrogenase kinases 1-4 (PDK) [
63
].  Of interest here is the PDK4 
isoform, which shows the highest level of basal activity among the PDKs [
63
].   
The action of PDK4 under normal circumstances is suppressed by insulin action.  
Starving conditions on the other hand promote the opposite trend, which is seen as a marked 
increase in Pdk4 transcript levels occurring 48 hours after food deprivation [
63
].  In T2DM the 
ability of insulin to suppress PDK4’s activity becomes hindered, which has devastating 
consequences that result in exacerbated hepatic glucose release.  The capacity of insulin to 
regulate Pdk4 expression is thought to occur through an intermediary protein called FOXO1 [
36
].  
This dysfunctional series of events, involving PDK4, perpetuates pre-existing hyperglycemia and 
therefore hyperinsulinemia as well. 
 
2.4.6  Hepatic glucose release by FoxO1  
 The forkhead transcription factor known as forkhead box class O 1 (FOXO1) was 
investigated here because of the keystone role it plays in energy metabolism and insulin 
signaling [
65
].  FOXO1 is typically in an unphosphorylated state and localized within the nucleus 
where it’s niche as a transcription factor serves as a prerequisite for the expression of several 
genes, including the aforementioned Pdk4 [
65
].  However, upon insulin stimulation (as well as by 
IGFs) a molecular cascade is initiated, via the phosphatidylinositol 3-kinase (PI3K)-Akt 
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pathway, which ultimately phosphorylates nuclear FOXO1 [
64,65
].  Phosphorylated FOXO1 is 
exported from the nucleus, effectively terminating the transcription of all FOXO-dependent 
genes [
65
].  The deleterious effects of insulin resistance become readily apparent upon 
examination of the genes whose transcriptions are FOXO1 dependent.  Insulin resistant tissues 
fail to deliver the inhibitory message to FOXO1, allowing it to remain in the ‘on’ state within the 
nucleus where it actively promotes gene transcription for several gluconeogenic proteins [
65
].    
Overactive FOXO1 (and its associate PCG-1α/PPARGC1) in the liver can be found to 
have profoundly negative consequences [
36,65
].  As mentioned above, several of the genes that 
undergo FOXO-mediated transcription are gluconeogenic factors that when activated facilitate 
glycogen breakdown, and yet again serve to further increase blood glucose concentration [
65
].  
This only perturbs the ongoing pathological dichotomy happening between hyperglycemia and 
hyperinsulinemia/insulin resistance. Contrary to the negative role FOXO1 potentially plays in the 
diabetic liver, studies performed using mice have demonstrated in the pancreas it can actually 
reverse beta cell failure through interactions with Pdx-1 [
66
].  The actions of FOXO1 are 
therefore understandably often described as being a double-edged sword. 
 
2.4.7  Ptpn1: Insulin signaling antagonist 
The Protein tyrosine phosphatase N1 (Ptpn1) gene was examined in the current study 
because of the significant role it plays as a negative regulator of insulin signaling.  It is located 
on the long arm of human chromosome 20, a region that has been strongly implicated in the 
heritability of T2DM [
67, 68
], which has placed it under heavy investigation by researchers as a 
potential therapeutic target in the treatment of insulin resistance [
67
].  To date 6 different 
naturally occurring haplotypes of Ptpn1 have been identified, each possessing a unique pattern of 
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SNPs.  One of these haplotypes is expressed by approximately 35% of people living in the 
United States.  Interestingly, 30% (1.3-fold increase in risk) of these carriers go on to develop 
full-blown T2DM, a percentage that sadly equates to roughly 3.6 million people (calculation 
based on 18 million diagnosed) [
68
]. 
The gene Ptpn1 encodes a ubiquitously expressed phosphatase called protein tyrosine 
phosphatase 1B (PTP1B) [
68
].  The role of PTP1B is to dephosphorylate the tyrosine residues on 
active insulin receptors (e.g. IRS-1) [
68
].  This activity disrupts insulin signaling on a global 
level, drastically increasing the severity of an insulin resistant state [
68
].  
Current research efforts have demonstrated that PTP1B-deficient mice, subjected to diet-
induced obesity and diabetes, experienced significantly better glycemic control and also had 
reduced plasma insulin levels compared to wild-type mice [
67, 68
].  This evidence further supports 
Ptpn1 as a candidate for therapeutic intervention. 
 
2.4.8  Slc2A4 (GLUT4): Glucose sensitivity 
 One of the main purposes served by the acute response phase of insulin is to promote 
cellular uptake of free glucose [
69
].  One primary mechanism for accomplishing this task is 
mediated by GLUT4 translocation, which at the level of muscle is solely responsible for as much 
as 70% of total glucose uptake [
70
].  GLUT4 is one isoform of glucose transporters transcribed 
by the Slc2A4 gene that is directly regulated by insulin signaling [
69
].  GLUT4 is temporarily 
recruited to the plasma membrane, where it serves the crucial role of translocating free blood 
glucose into the cell via facultative diffusion [
70
].  Interestingly, GLUT4 receptors have been 
shown to be internalized up to twenty-times faster than they are recruited to the membrane, 
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which allows for a rapid correction in cellular metabolism [
70
].  The relative density of GLUT4 
receptors at the cell surface is primarily what dictates the extent of glucose uptake (i.e. glucose 
sensitivity and glucose tolerance).   
 
 
Figure 4.  Generalized overview of molecular mechanisms involved in glucose and insulin 
metabolism 
 
*Note: The liver is portrayed for illustrative purposes only; the mechanisms shown don’t 
necessarily represent hepatic pathways (e.g. GLUT2 is primarily expressed in hepatic and 
pancreatic tissue, while GLUT4 is found in skeletal muscle and adipose tissue) 
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2.5  O-GlcNAc: The Chief Nutrient Sensor 
In 1983 Torres and Hart made the profound discovery of a post-translational modification 
by β-O-linked N-acetylglucosamine (O-GlcNAc) [71].  Investigators have since demonstrated its 
actions are vital to maintaining a broad number of cellular functions, and that aberrant O-
GlcNAc cycling is likely to be involved in the pathogenesis of human illnesses such as T2DM, 
cardiovascular disease, X-linked Dystonia Parkinsonism, Alzheimer’s disease, as well as several 
other neurodegenerative and metabolic ailments [
71
]. These observations have made O-GlcNAc, 
and the two enzymes that facilitate its cycling, alluring targets for novel drug therapies. Even 
more intriguing, however, is their strong potential to be used as predictive biomarkers of disease 
[
72
]. 
As of today researchers have identified well over 3,000 proteins that undergo 
modification by O-GlcNAc, including a myriad of different regulatory elements such as 
transcription factors, methyltransferases, RNA polymerase II, histone cores and tails, nuclear 
pore receptors, steroid receptors, phosphatases and kinases, as well as oncogenes and tumor 
suppressors (figure 5) [
71
]. This vast and diverse catalogue of O-GlcNAc modified proteins 
continues to grow, strengthening support for the ubiquitous and pivotal role it plays not only in 
glucose metabolism but also cellular signaling, protein transport and stability, as well as 
chromatin remodeling and gene transcription  [
71
]. 
 
2.5.1  What makes O-GlcNAc so different? 
O-GlcNAc modification is a process very different from all other forms of glycosylation 
that, oddly enough, shows more similarity to protein phosphorylation [
71
]. O-GlcNAc is 
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considered to be one of the most abundant post-translational modifications within the nucleus, 
the cytoplasm, as well as the inner membrane of the mitochondria [
71,73,74
]. This attribute 
distinguishes O-GlcNAc from other N- and O- glycans, which are typically confined to the 
lumen of the endoplasmic reticulum or golgi apparatus [
71
]. Additionally, mature O-GlcNAc is 
generally unmodified and has a half-life that extends for a duration long enough to cycle on and 
off target proteins several times [
71
]. 
 
2.5.2  Detecting the elusive β-O-GlcNAc 
Although nearly three decades have passed since Hart and Torres’ first discovered O-
GlcNAcylation (i.e. modification by O-GlcNAc) it still remains among researchers, more often 
than not, an esoteric form of post-translational modification. The general lack of awareness is an 
understandable product for any molecular event capable of eluding some of the most advanced 
screening techniques used in the field of proteomics, including both mass spectrometry and SDS-
PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) [71]. 
The inconspicuous nature of O-GlcNAc modification is primarily a result of three 
fundamental attributes. First, unlike modifications by phosphate the cycling of O-GlcNAc has 
virtually no effect on the net charge of it’s host species and is therefore unlikely to produce any 
noticeable change in migration during SDS-PAGE [
71
].  Secondly, techniques that physically 
irradiate samples, including electrospray mass spectrometry and matrix-assisted laser desorption 
time-of-flight (MALDI-TOF), are unable to detect the substoichiometric amount of peptide-
bound O-GlcNAc because it is quickly lost during the ionization step [
71
].  Third, cell lysis or 
damage causes ubiquitously high levels of hydrolases (e.g. lysosomal hexosaminidases and 
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nucleocytoplasmic β-N-acetylglucosaminidases), which are present in all cells, to promptly 
remove O-GlcNAc [
71
]. 
However, in recent years these obstacles have been overcome with improvements made 
to mass spectrometry as well as by using newly developed monoclonal antibodies [against O-
GlcNAc] and potent inhibitors for β-N-acetylglucosaminidases [71].  During the two decades 
preceding these developments progress was sluggish, but with their arrival the productivity of 
researchers catapulted forward and our understanding of the role played by O-GlcNAc sharply 
improved. 
 
2.5.3  Overview of O-GlcNAc cycling 
Approximately 2-5% of all incoming cellular glucose is shunted towards the ‘nutrient 
sensing’ Hexosamine Biosynthetic Pathway (HBP), where the terminal product is the high-
energy sugar donor for O-GlcNAc called Uridine diphosphate N-acetylglucosamine (UDP-
GlcNAc) [
71,73,74
].  The initial flux of glucose towards the HBP is the trigger that primes a 
molecular cascade of events that all eventually become subject to a bottleneck effect created by 
the enzyme called D-fructose-6-phosphate amidotransferase 1 (GFPT1), or simply GFAT [
71,74
].  
Glucose becomes fully committed to the Hexosamine pathway after enzymatic modification by 
GFAT, a role that has branded GFAT as the primary regulator for UDP-GlcNAc synthesis and 
key component involved in governing total cellular O-GlcNAcylation [
71,74
].  
Protein modification by O-GlcNAc occurs when the N-acetylglucosamine moiety of 
UDP-GlcNAc is enzymatically transferred onto a serine or threonine residue, forming a 
glycosidic link that lasts anywhere from seconds to minutes [
71
].  This heavily investigated 
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process lead researchers to take notice of O-GlcNAc’s high potential for dynamically interacting 
with serine/threonine phosphorylation, making its role much more complex than was ever 
previously anticipated [
71,73,74
].   
 
2.5.4  Dynamic interactions with protein phosphorylation 
In many respects O-GlcNAcylation and phosphorylation exhibit a yin-yang type 
relationship, which can be seen by their tendency to cycle in reciprocity on-and-off adjacent, if 
not the same, residues.  In fact, nearly every phosphorylation site undergoing active cycling is 
influenced by O-GlcNAcylation [
75
].  Protein phosphatase 1 (PP1c) for instance has been shown 
to form a complex with OGT, in which they act in unison to simultaneously facilitate the 
replacement of O-phosphate with O-GlcNAc [
71
].   There are however distinctive characteristics 
separating the two enzymatic processes, the hallmark being that unlike protein phosphorylation, 
which utilizes hundreds of different kinases and phosphatases, protein O-GlcNAcylation is an 
event mediated by just two enzymes: uridine diphospho-N-acetylglucosamine:peptide β-N-
acetylglucosaminyltransferase (O-GlcNAc Transferase; OGT), and N-Acetyl-D-glucosaminidase 
(O-GlcNAcase; OGA) [
71,73,74
].  The concerted action between these enzymes dictates the rate at 
which N-acetylglucosamine is added and removed from proteins, respectively, and any 
disruption that off sets their delicate balance has potential for causing system-wide catastrophe. 
 
2.5.5 O-GlcNAc cycling enzymes  
O-GlcNAc cycling is mediated by two highly conserved enzymes, which to date have 
been found in nearly every multi-cellular organism examined [
71
].  In animals the enzymes that 
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facilitate this process are called OGT (O-GlcNAc Transferase) and OGA (O-GlcNAcase), each 
of which is encoded by a single gene [
71,73
].  The only exception to this is found to occur in 
Arabidopsis, which appear to have two genes responsible for encoding OGT [
76
].  The precise 
and concerted activity between OGT and OGA is momentously important for dozens of 
signaling pathways and a broad range of other cellular functions (figure 5).  Gene transcription 
for instance is an event arbitrated by the O-GlcNAc moiety, which can be seen cycling on- and 
off- the transcriptional initiation complex of RNA Polymerase II; the former acting to block 
transcription [
71,73
].  
The role played by OGT and OGA is one that if dysfunctional has a high potential to not 
only disrupt insulin signaling but also cause unabated cellular proliferation [
71,73,74
].  A thorough 
explanation of OGT and OGA’s complex biology would require volumes of information. 
Therefore, the following sections will briefly address the key structural and chemical features of 
each enzyme, providing insight into why their involvement has been implicated in the 
pathogenesis of T2DM. 
 
2.5.5.1  O-GlcNAc Transferase 
 Recombinant gene studies (e.g. Cre-recombinase technologies like Cre-loxP) and 
conditional knockouts of O-GlcNAc transferase have proven it to be an unassailable requisite for 
embryogenesis and stem cell viability [
77,78
].  In addition to the essential role it plays for mouse 
ontogeny, researchers have demonstrated that deletion of Ogt is lethal in all organisms except for 
Caenorhabditis elegans (C. elegans), who instead are found to become lethargic [
79
].  
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The solitary gene that encodes for OGT shows over 99% homology between mice and 
humans, and it spans a distance of ~42 Kb on the long arm of the X chromosome (human 
Xq13.1) [
80,81
].  Its 23 exons are so far known to encode for three separate isoforms that can be 
found in varying concentrations within all human tissues, although pancreatic α/β cells and the 
brain are known to be the most abundant [
71,82-84
].   
Each isoform is comprised of three parts: a C-terminal catalytic domain, a linker region, 
and finally an N-terminus containing a tetratricopeptide repeat motif (TPR), which differs in 
length for each transcript [
80
].  The longest isoform is a ~110-116 kDa nucleocytoplasmic protein 
encoded by all 23 exons, and is found to have an optimum pH existing around ~6.8 [
85
].  To no 
coincidence this also happens to be a pH that falls in close proximity to the acidotic environment 
common to pathologies like obesity and cancer.   
At ~103 kDa the next longest transcript, termed mOGT, contains a unique mitochondrial-
directing N-terminus that is encoded by exons 5-23 [
86
].  Interestingly, unlike its counterparts the 
overexpression of mOGT has been found to cause notable levels of cytotoxicity, and is therefore 
considered a pro-apoptotic isoform [
87
].  In contrast, the last and shortest transcript, sOGT (~78 
kDa), appears to exhibit anti-apoptotic tendencies [
87
].  Just like ncOGT, sOGT is a ubiquitously 
active protein localized within both the nucleus and cytoplasmic compartments [
67, 80
].   
Several regulatory mechanisms have been identified that mediate the transcriptional 
activity of Ogt.  Such examples include enzyme-activating tyrosine phosphorylation (e.g. 
CaMKIV transcriptional feedback loop) as well as self-induced O-GlcNAcylation (whose role is 
not yet fully understood) [
88
].  The most notable means of regulation, however, is thought to 
involve negative feedback imposed by free UDP that is released upon the transfer of GlcNAc to 
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target proteins [
82
]. 
 
2.5.5.2  O-GlcNAcase  
O-GlcNAcase, or OGA, is a pH neutral enzyme that is primarily found within the 
cytosolic compartment of cells and shares 97.8% identity between mice and human gene [
81
].  
The gene that encodes for OGA was cloned and found to be identical to the hyaluronidase gene 
meningioma-expressed antigen 5 (MGEA5) [
89
].  It’s composed of a glycosidase domain located 
at the N-terminus, with a histone acetyltransferase (HAT) domain at the opposite carboxyl 
terminal [
90
].  The HAT domain shows remarkable homology to the GCN5 HAT family, which 
allows OGA to serve the dual purpose of removing the O-GlcNAc moiety from modified 
proteins while also having the capacity to acetylate histones thereby activating gene transcription 
[
89,91
] 
Oga resides on the human locus 10q24.1, which is a region juxtaposed to the insulin-
degrading enzyme that has been implicated in the pathology of both Alzheimer’s disease as well 
as the etiology of transgenerational T2DM [
78,81,92-94
].  A specific example can be seen among 
individuals of Mexican American ethnicity who are known to exhibit a uniquely high 
susceptibility to developing a T2DM phenotype [
95
].  The elevated risk experienced in this 
population of people may be due to a point mutation that causes an early termination of OGA 
during translation, which leads to an enzyme deficiency that is quickly outmatched by OGTs 
activity. 
Furthermore, O-GlcNAcase offers a high potential for use as a biomarker to detect T2DM 
[
96,97
].  Although both OGA and OGT are expressed in human erythrocytes, only OGA exhibited 
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statistical significance for its ability to outperform HbA1c as a test for detecting pre-diabetes and 
diabetes (two and three fold increases in the expression levels, respectively; n=13/14 p ≤ 0.01) 
when compared against HbA1c levels [
97
].  The HbA1c is a sensitive and specific test commonly 
used for diagnostic purposes when screening for T2DM.  However, the study referenced here 
found OGA to be a more sensitive and reliable method for detecting pre-diabetes [
97
]. 
 
2.5.6  A Word on epigenetic regulation by O-GlcNAcylation 
In many respects O-GlcNAcylation is a process that generates continuity in a nutrient-
based molecular circuit, designed to interface our dietary habits to the transcriptional activity of 
our genome.  O-GlcNAc was officially inducted into the “Histone Code” after several 
investigations witnessed its cycling activity directly influenced epigenetic machineries like 
acetylation, ubiquitylation, and methylation [
71,78,91,92,94
].  Sakabe et al. (2010) additionally found 
O-GlcNAc to interact with polycomb group proteins (PcG), and alter higher order chromatin 
structures on all four histone cores including H2A, H2B, H3 and H4 [
91
].   
In addition to OGA’s histone acetyltransferase domain described in the previous section, 
the O-GlcNAc moiety has also been shown to interact with several methyltransferases including 
mixed-linease leukemia 5 (MLL5), coactivator-associated arginine methyltransferase 1 
(CARM1), and Whc1 (
92
).  One additional example recently discovered by Chen et. al. (2012), 
was O-GlcNAc’s propensity to interact with ten eleven translocation enzymes (TET) [98].  
Specifically, they found OGT-dependent histone O-GlcNAcylation to be facilitated by TET2 and 
TET3 enzymes.  Moreover, these enzymes appeared to target O-GlcNAc to transcriptional start 
sites on histone 2B.  Although the facts presented here only reflect a small portion of the 
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evidence compiled to date, they are an effective demonstration of the significant role O-GlcNAc 
plays in regulating the epigenome.  
 
 
Figure 5. Epigenetic and metabolic regulation by O-GlcNAcylated proteins. 
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3.0  Materials and Methods 
3.1  Approach 
An animal model consisting of genetically identical inbred C57BL/6J mice (Jackson 
Laboratories) was employed to study the epigenetic modifications that contribute to an increased 
risk of childhood obesity and diabetes.  In order to effectively measure epigenetic markers of 
paternal origin only founder fathers were exposed to experimental conditions, while mothers 
were maintained on a control diet and used exclusively for breeding purposes.  All procedures 
and tissue collection methods were conducted in a humane manner with the approval of the 
Institutional Animal Care and Use Committee (IACUC) of East Carolina University. 
 
Figure 6. Timeline of experimental design 
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3.2  Animal Housing Conditions and Diet 
 C57BL/6J mice were obtained from Jackson Laboratory and bred on site at East Carolina 
University for two generations to eliminate any confounding variables associated with the 
transition in living conditions.  The third generation of male mice born at East Carolina served as 
the founder generation (F0), and at 4-weeks of age were divided into three experimental groups: 
control-diet fathers (CF), high-fat diet fathers (FF), and control-diet exercise fathers (EF) housed 
with free access to a running wheel.  When F0 fathers reached 16-weeks of age they were 
temporarily housed with a pair of control females for a duration of 3 days to produce the F1 
generation of offspring.  F1 mice were weaned at post-natal day 21 and at 4-weeks of age were 
assigned to either a control diet or high-fat diet for a duration of 12 weeks, at which time they 
were used to breed an F2 generation of offspring.  After breeding, all male mice were sacrificed 
for tissue collection.  Control diets consisted of 10% energy derived from fat (D12450; Research 
Diets, Inc., NJ, USA), while high-fat diets were 60% energy derived from fat (D12492I; 
Research Diets). All animals were fed ad libitum and housed individually in a climate-controlled 
environment maintained at 24 °C with 50% humidity, on a 12-hour light/dark cycle. 
 
3.3  Wheel Cages and Exercise 
Exercise fathers (EF) were housed individually and given free 24-hour access to a 
running wheel.  Cages for exercising fathers were slightly larger than others to accommodate 
room for their wheel.  Revolutions were actively monitored, and transmitted, by sensors 
connected to an automated computer system designed to tabulate activity.  Only the animals 
found to run an average of 3 miles per day, over the course of the 12-week exercise regimen, 
were chosen for breeding and for inclusion in other tests.  
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3.4  Developmental Monitoring 
Developmental milestones were recorded on mice during post-natal days 7-14.  The 
following parameters were measured: body weight, the time at which upper and lower incisors 
erupted, fur appeared, eyes opened, and ear flaps had separated from head. Considerable efforts 
were made to minimize the length of time spent interacting with pups, and also to preventing 
scent carry-over between different litters. 
 
3.5  Weight and Adiposity Measurements 
At four weeks of age mice were subjected to body composition testing using an 
EchoMRI-700 machine (EchoMRI, Inc., TX, USA), and each week until mice were sacrificed 
the following parameters were measured: percent fat, free water, total water and lean mass, 
which is defined by manufacturer as the total biomass of muscle tissue and all body parts 
containing water; excluding fat, bone, hair, and claws. As suggested by the manufacturer, before 
each use of the EchoMRI it was calibrated for mice by using an appropriate volume of canola oil, 
which has been shown from NMR chemical analysis to accurately reflect the signal recorded 
from fat molecules.  
 
3.6  Metabolic Profiling 
F0 and F1 generation animals were temporarily housed in metabolic cages to evaluate the 
effects of diet and free wheel running.  Metabolic performance was measured at 0-, 6-, and 12-
weeks, with respect to time of diet assignment, via indirect open-circuit calorimetry (LabMaster 
36 
 
Software; TSE-Systems, MO, USA).  At the 0-week time point all mice were consuming the 
same control diet.   
Metabolic chambers (i.e. calorimetric modules) were equipped with the following 
components: food and water dispensers attached to independent balances, perimeter sensors used 
to assess total, ambulatory, or fine movement, and lastly each cage included high-speed 
paramagnetic gas sensing units to monitor respiration. Gas sensors were calibrated prior to each 
session using primary gas standards containing known concentrations of N2, O2, and CO2.  A 
mass air flow meter was used to validate rate of airflow.   
Animals were transferred to clean metabolic cages between the times of 0900-1200 on 
Thursday and then removed at 0900 the following Monday.  The first day served as a period of 
acclimation, with measurements used for statistical purposes beginning Friday at 0700 and 
ending Monday at 0700.  All mice were weighed upon their removal from metabolic cages. 
Parameters measured at 20-minute intervals include the following: total activity (x-, y-, z- 
axes), food and water consumption, CO2 production and O2 consumption (ml/h/kg).  Energy 
expenditure was derived by the following equation:  (((3.941*VO2)+(1.106*VCO2))/1000)/(total 
body weight/1000), which served to adjust the respiration exchange rate by body weight (grams). 
 
3.7  Glucose Tolerance Testing and Plasma Insulin 
 Glucose metabolism was assessed at 0-, 6, and 12- weeks with respect to time of diet 
assignment.  Mice were transferred to the procedure room four hours prior to testing, at which 
time their food was removed to simulate fasting conditions (fasting time 0700-1100).  Blood was 
first collected from the tail caudal vein to establish baseline values for glucose and plasma 
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insulin concentrations.  Immediately following the initial blood collection mice were injected 
intraperitoneally with a 50% dextrose solution (dose dependent on lean body mass).  Plasma 
insulin was measured again 30 minutes after injection while glucose was measured again at 30, 
60, and 120 minutes.  Glucose concentration was determined with a glucometer (Alpha-Track 
Glucometer; Abbott Laboratories, CA, USA).  All precautions were taken to minimize animals 
stress level.  Additionally, in an effort to reduce variation within data collection processes all 
personnel assisting on glucose tolerance testing were kept constant. 
Quantification of plasma insulin was performed on approximately 50 μl of blood 
collected by a glass capillary.  Plasma was isolated from whole blood by centrifuging for 10 
minutes at 10,000 × g (4 °C).  Isolated plasma was then processed using the Rat / Mouse Insulin 
ELISA Kit from Millipore (MA, USA), and absorbances were subsequently read at 450 nm and 
590 nm using a LKB Biochrome 4050 Ultrospec II UV/Vis Spectrophotometer (MN, USA). 
 
3.8  Tissue Collections and Processing 
After 12-weeks of diet or exercise mice were individually euthanized by isoflurane 
overdose followed by decapitation.  White and brown adipose tissue, liver tissue, pancreatic 
tissue, and gastrocnemius muscle were collected immediately after death and snap frozen in 
liquid nitrogen.  All samples were later transferred to a -80 °C freezer for permanent storage. 
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3.9  Protein Extractions and Downstream Processing 
 Protein was isolated from gastrocnemius muscle, pancreas, and liver to examine OGT 
and OGA protein expressions. Whole tissue lysates (10% weight/volume) were processed and 
suspended in the following mixture: 10 μl/ml of protease inhibitor cocktail (P8340; Sigma-
Aldrich, MO, USA) and 10 μl/ml of phenylmethanesulfonyl fluoride (PMSF) combined with 
radioimmunoprecipitation assay buffer (RIPA) - [50mMTris-HCL, 150mMNaCl, 1mM 
ethylenediaminetetraacetic acid (EDTA), 0.1% SDS, 0.5% Sodium Deoxycholate, and 1% Triton 
X-100, pH 7.8].  Mechanical disruption and homogenization were performed on ice by 2× 0:15 
pulses using a PowerGen 700 polytron set to maximum speed (Fisher Scientific Inc, MA, USA).  
The homogenate was then centrifuged for 12 minutes at 10,000 × g (4 °C), and the supernatant 
then transferred to a clean 1.5 ml tube.  To determine protein concentration a Bradford assay was 
performed on a Bio-Rad SmartSpec 3000 spectrometer (Bio-Rad Laboratories, PA, USA).  
Samples were measured in duplicate and prepared as follows: 750 μl dH2O, 50 μl diluted protein 
(1:10), and 200 μl Bio-Rad Protein Assay Dye (Bio-Rad Laboratories). A standard curve was 
generated at the start of each protein assay using a series of dilutions prepared by adding 200 μl 
of Bio-Rad Assay Dye to the following pre-mixed tubes containing dH2O/BSA (μl): 800/0, 
798/2, 796/4, 784/16, 760/40, 720/80.  
 
3.9.1  Western Blot Analysis 
Protein expression was measured by Western blot analysis. Samples were made western-
ready by mixing approximately 15 μg of protein with 4×NuPAGE LDS Sample Buffer, 10× 
Reducing Agent (Life Sciences, NY, USA), and dH2O.  Sample preparations were then boiled 
for 5 minutes.  Proteins were analyzed under reducing conditions (NuPAGE Reducing Agent) 
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with MES SDS running buffer on 4-12% Bis-Tris gels (Life Sciences, USA).  Samples were 
transferred to polyvinylidene difluoride membranes (PVDF; Life Sciences, USA) by 
electroblotting for 7 minutes at 25V using the iBlot Dry Transfer System (Life Sciences).  Equal 
loading of samples was confirmed by Ponceau staining [0.25 g Ponceau-S, 40 ml methanol, 15 
ml Acetic Acid, 45 ml dH2O] and by using the housekeeping protein α-tubulin as an internal 
control (1:500 dilution).  Following transfer, PVDF membranes were blocked at room 
temperature for 1 hour in a 1:1 mix of PBS and Odyssey Blocking Buffer (LI-COR, NE, USA) 
and then incubated overnight at 4 °C with primary antibodies. Primary antibodies cocktails were 
prepared with following ingredients: rabbit polyclonal anti-OGT diluted to 1:2000 (AL25; a kind 
gift from Dr. Gerald Hart, Johns Hopkins Institute, Baltimore, MD, USA) in a 1:1 mixture of 
Odyssey blocking buffer and PBST (0.2% Tween). Anti-OGA (C345 isoform; also a generous 
donation provided by Dr. Gerald Hart of Johns Hopkins Institute) was diluted to 1:6000 in the 
same manner described for OGT.  After incubating membranes with primary antibodies they 
were washed with 0.1% PBST for 10 minutes (4×) and 20 minutes (1×).  Subsequent to washing 
the membranes were subjected to a second blocking step (30’ at room temperature) to reduce 
potential for non-specific binding of secondary antibodies.  
 Secondary incubation was carried out at room temperature, for 1 hour, in complete 
darkness.  Two-channel detection for OGT+α-tubulin or OGA+α-tubulin was accomplished 
using secondary antibodies derived from different host species.  Solutions used for secondary 
incubation were prepared as follows: a 1:1 mix of Odyssey blocking buffer and PBST (0.2% 
Tween), 0.01% SDS, 1:15,000 goat-anti-mouse [680λ detection of α-tubulin] (LI-COR), and 
finally either 1:15,000 goat-anti-rabbit [for OGT at 800λ] (LI-COR) or with 1:5,000 donkey-anti-
chicken [for OGA at 800λ] (LI-COR). To finish, 5× 5-minute washes and 1× 10-minute wash 
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were performed using PBST (0.1% Tween).  Membranes were kept wet in PBS and visualized 
by 2-channel chemiluminescence with an Odyssey CLx Infrared Imaging System (LI-COR).  
Upon initially receiving secondary antibodies their specificity was validated by performing a 
secondary incubation, as described above, on a negative control PVDF membrane (i.e. protein-
loaded PVDF membrane, not previously exposed to primary antibodies) 
 
3.10  RNA Isolation and Downstream Processing 
Approximately ~25mg of solid frozen tissue was processed by using the mirVana 
miRNA Isolation kit (Ambion, CA, USA).  Tissues were kept on dry ice until being transferred 
to the appropriate volume of Lysis/Binding Buffer (1:10 for liver, 1:6 for pancreas and muscle). 
Samples were kept on ice during mechanical homogenization for a duration of 30 seconds 
(2×0:15 pulses) using a PowerGen 700 polytron (Fisher Scientific).  Organic extraction was then 
performed using acid-phenol:chloroform (5:1 solution pH 4.5 ± 0.2).  All subsequent steps were 
conducted in accordance to the standard mirVana protocol provided by the manufacturer.  RNA 
was eluted with nuclease-free H2O (78 °C) and then treated with DNase (Ambion DNA-free kit, 
Cat. #AM1906) to ensure samples were free of genomic DNA contamination.  RNA 
concentration was determined using a NanoDrop UV-Vis ND-1000 spectrometer (Fisher 
Scientific) and purity was evaluated by the observed A260/A280 ratio (2.00±0.08).  Eluted RNA (2 
μg) were prepared for RT-PCR with the Superscript Vilo Kit (Invitrogen, NY, USA).  Upon 
completion of cDNA synthesis all samples were adjusted to a final concentration of 5 ng/μl 
before analyzing by real-time PCR. 
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3.10.1  Semi-quantitative Real-Time PCR: cDNA 
  Semi-quantitative real-time PCR was performed on an ABI 7900HT sequence detection 
system with SDS 2.3 software (Applied Biosystems, CA, USA).  Samples were loaded in 
triplicate and NTCs in duplicate onto Bio-Rad 384-Well PCR plates (Bio-Rad Laboratories, 
USA; Item #HSR-4805). Each 10 μl reaction consisted of 5μl Power Sybr Green Master Mix 
(Invitrogen, USA), 3.6 μl nuclease-free H2O, 200mM forward primer, 200mM reverse primer, 
and 1 μl cDNA template (5 ng/μl).  After loading samples, plates were sealed and centrifuged for 
1 minute 900 × g at 4°C.  Two-Step PCR cycling conditions used were as follows: 2:00 at 50°C// 
10:00 at 95°C// 0:15 at 95°C/1:00 at 60°C (40 cycles)//0:15 at 95°C/0:15 at 60°C.  Target gene 
transcripts were normalized against the reference gene β-actin, and calculated ΔΔCT2 values 
were used to represent relative gene expression [
99
]. 
 
3.11  DNA Isolation and Downstream Processing 
 Approximately 20-30 mg of frozen tissue was processed with the Qiagen DNeasy Blood 
& Tissue Kit (Qiagen Inc., CA, USA).  All steps were carried out according to the 
manufacturer’s instructions with three exceptions. Firstly, tissues were optionally disrupted by 
mechanical homogenization (2 × 10 seconds; PowerGen 700 polytron) prior to digesting with 
Proteinase K (2:30hr/56 °C).  Second, all samples were treated with 4 μL of RNase A to ensure 
there was no RNA carry over (Qiagen, USA; Item #19101). The last deviation from protocol was 
made by performing two successive elutions with 50 μL (68 °C) of a TE buffer mix.  The TE 
buffer mixture was a 1:4 composition of Ambion TE (Ambion, USA; AM9849) and Qiagen AE 
buffer (Qiagen, USA; 19077). This combination of TE buffers offers an optimum pH and EDTA 
(ethylenediaminetetraacetic acid) concentration to promote DNA stability with minimal risk of 
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intercalating and sequestering, MgCl ions during active PCR reactions.   
 
3.11.1  Sonication and Agarose Gel Electrophoresis   
Isolated DNA samples were subsequently sonicated to obtain an average fragment size of 
~150-750bp.  Fragmentation was achieved with a Misonex 4000 Sonicator (Misonix, Inc., NY, 
USA) using a cup-horn attachment. Using indirect sonication via a cup horn (i.e. water bath) was 
preferred over use of a probe sonicator, as the former reduces risk for cross-contamination 
(samples are kept sealed) and also allows for batch processing.  Samples (100 μl /vial) were 
floated approximately ~2 mm above the resonating platform, and sonicated for a duration of 10 
minutes at maximum amplitude (30 second on/off intervals).  The water bath was drained and 
refilled with ice-cold water every 2 minutes.  DNA concentration and purity (A260/A280 
ratio1.80±0.2) were measured in duplicates using a NanodropND-1000, and then diluted to a 
final concentration of 15 ng/μl before storing at -80°C. 
 Gel electrophoresis was used to verify DNA integrity, purity (i.e. RNA contamination) 
and fragment sizes.  Agarose gels were mixed to a concentration of 1.75% with the following 
components: 0.445 grams of agarose powder  dissolved in 32 ml dH20, 8 ml 10× TBE (1× final), 
and 0.8 μl ethidium bromide (EtBr). The liquid agarose was poured to a depth of 6 mm in a clean 
5 × 8 cm casting tray and allowed to cool for 30 minutes.  Running buffer (1× 1M TBE) was 
prepared with 204 ml dH20, 51 ml of 10× 1M TBE, and 2 μl EtBr.  Upon filling the 
electrophoresis tank with running buffer an additional 4 μl of EtBr was mixed at the anode 
terminal.  Ethidium Bromide migrates in an opposing direction to that of DNA; therefore this 
step was performed to increase the potential number of collisions between EtBr and DNA, which 
effectively increasing the fluorescence of samples.  Stock 10× TBE, used for gel and buffer 
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preparation, was made by dissolving the following ingredients in 1 liter of deionized water: 108 
grams Tris-base, 55 grams boric acid, and 7.5 grams EDTA.  Lanes were loaded with a 10 μl mix 
that consisted of 500 ng DNA, 2 μl of 5× sample buffer (Bio-Rad Laboratories, USA), and 
nuclease-free H2O used to adjust the final volume.  Samples were run for 01:10 hours at constant 
voltage (100V) and immediately visualized on a UV transilluminator (AlphaEaseFC software; 
Alpha Innotech, FL, USA).  A 100-1000bp molecular ladder was loaded adjacent to samples to 
assess the extent of DNA fragmentation (Bio-Rad Laboratories, USA). 
 
 
Figure 7. Agarose gel electrophoresis illustrating optimized sonicatication conditions.  DNA 
is fragmented to an average size of 200 – 500 bp.   
 
 
 
1 Kb 
CFO   CFO     CFO      EFO      EFO      EFO      FFO      FFO      FFO 
500 ng/lane  muscle genomic DNA 
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3.11.2  Methylation Capture 
 Methylated regions (≥ 4 CpG’s) of input DNA were enriched by a capture reaction using 
the human MBD2 protein (Methyl-CpG Binding Domain Protein 2) coupled to paramagnetic 
beads via a biotin linker (MethylMiner Kit #ME10025; Invitrogen, USA). MBD-cap (Methylated 
Binding Domain-Capture) was performed according to the manufacturer’s suggested protocol 
with a few minor adjustments, which are described below.  Use of the MethylMiner kit was 
validated with two synthetic duplex DNAs (non-methylated and methylated DNA) that served as 
controls and were processed in the same manner as other samples. Approximately 1 μg of input 
DNA was loaded for methylation enrichment.  MBD-protein only recognizes double stranded 
DNA, thus it was decided to incubate samples overnight at 4°C to reduce any risk of heat-
induced DNA dissociation.  CpG-methylated DNA was eluted as a single fraction using a high-
salt buffer solution (2000mM NaCL), as opposed to a step-wise elution with a series of buffers 
of increasing NaCl concentration.   
Ethanol precipitation was performed to clean up the methylated DNA.  This was 
accomplished by incubating samples at -80 °C for a minimum of 3 hours with the following 
components: 1.5 μl glygogen (20 μg/μl), 40 μl of 3 M sodium acetate pH 5.2, and 800 μl of 
100% ethanol.  After incubation, samples were centrifuged for 15 minutes 16,000 × g at 4 °C and 
the supernatant discarded.  Approximately 500 μl of ice-cold 70% ethanol was then added and 
samples were centrifuged for 5 minutes at 16,000 × g at 4 °C (repeat 1×).  Following the third 
round of centrifugation the supernatant was removed using a sterile glass micropipette attached 
to a vacuum aspirator.  The resulting DNA pellet was air dried for ~10 minutes at room 
temperature and then resuspended in 80 μl of the same TE buffer mix described above in 
Methods for DNA isolation. 
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3.11.3  Semi-quantitative Real-time PCR: Genomic DNA 
 To determine the relative density of methylation (fold enrichment) in promoter 
sequences, input DNA and MBD-cap DNA for each animal were subjected to PCR on the same 
ABI 7900HT machine used for gene expression analysis.  All preparatory methods described 
were carried out on ice and in low-light conditions.  Reactions were loaded in triplicate onto 384-
well PCR plates at a volume of 10 μl.  Master Mix preparations consisted of the following 
components: 5 μl Sybr Select Master Mix (Invitrogen, USA), 250mM forward primer, 250mM 
reverse primer, and 2.6 μl of nuclease-free H2O.  Approximately 8μl of Master Mix was 
dispensed to each well and then 2 μl of template DNA subsequently added.  NTC (No Template 
Control) reactions were run in duplicate for each gene by adding 2 μl of nuclease free water in 
lieu of template DNA.  After loading and sealing the PCR plates, they were centrifuged for 1 
minute 900 × g at 4 °C. 3-Step PCR cycling conditions used to amplify templates were as 
follows: 2:00 at 50°C // 2:00 at 95°C // 0:20 at 95°C / 0:25 at 59.5°C / 0:45 at 72°C (40 cycles) // 
0:15 at 95°C / 0:15 at 60°C / 0:15 at 95°C.  Amplification values were normalized against the 
house keeping gene β-actin and ΔΔCT2 was calculated for both input and methylated samples 
[
100
].  
To assess methylated enrichment (i.e. fold change relative to input) of targeted promoter 
sequence the following equation was used, and then normalized against controls: ((methylated 
ΔΔCT2/ input ΔΔCT2)*100).  Results obtained using this method reflect a general degree of 
methylation; more precise quantification would necessitate PCR also be run on unbound DNA 
and multiple wash fractions collected during MethylMiner. 
 
46 
 
3.12  Primer Design and Optimization  
All genomic primers were designed to flank a 75-150 bp amplicon within the promoter 
region of each target gene (table 2).  Promoter sequences all consisted of the nucleotides situated 
within -1200 bp /+200 bp of the transcriptional start site (TSS) or the first exon.  The only 
exception being for the gene h19 whose primers were designed to flank a unique sequence, 
referred to here as the Imprint Control/Promoter-Region (IC/P-R), which is located ~2 kb 
upstream from the first exon.  Primers were generated using Primer3 Version 0.4.0 [5] and 
blasted against the built-in mispriming database for rodents. To verify primer selections all 
sequences were subsequently screened using Vector NTI software (Life Technologies, USA).  
Desalted oligonucleotides were purchased from Invitrogen (NY, USA), and optimum annealing 
temperatures were established by running a PCR thermal gradient (annealing temperature range 
of 52°C-67°C) on a Bio-Rad C1000 Thermal Cycler (Bio-Rad Laboratories, USA).   
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Table 2.  Genomic and cDNA primer sequences used in PCR reactions. 
 
 
 
 
 
 
Target Gene Name Forward Primer Sequence Reverse Primer Sequence
Ogt GACGCAACCAAACTTTGCAGT TCAAGGGTGACAGCCTTTTCA
Oga (Mgea5) GGGTTATGGAGCAGAGAAAAGAG CCTGGCGAAATAGCATAGATGAA
Pdk4 AGGGAGGTCGAGCTGTTCTC GGAGTGTTCACTAAGCGGTCA
Ptpn1 GGAACTGGGCGGCTATTTACC CAAAAGGGCTGACATCTCGGT
Glut4 (Slc2a4) GTGACTGGAACACTGGTCCTA CCAGCCACGTTGCATTGTAG
cDNA Ppargc1α AACCAGTACAACAATGAGCCTG AATGAGGGCAATCCGTCTTCA
Igf2 GTGCTGCATCGCTGCTTAC ACGTCCCTCTCGGACTTGG
H19 CCTTGTCGTAGAAGCCGTCTG GGGTAGCACCATTTCTTTCATCT
FoxO1 AACCAGCTCAAATGCTAGTACCATC CAGAAGGTTCTCCATGTTTTTCTGGA
Gfpt1α GCCGAGCTGTGCAAACTCT GGCTGCTCAAAAATTTCCTTC
Ins2 GACCCACAAGTGGCACAAC TCTACAATGCCACGCTTCTG
Ogt CCCATAGGGAGCCCTTAACC GCGTAACAAGACTACCGACC
Oga (Mgea5) GGCGCCCTTTGTCCTTTT CGCTTCCTGTTTATCCGCAC
Pdk4 CTCCTCCCTCTCACCCTTTG AACTTTGGGCTCCTCCCTTT
Ptpn1 TGGAGAAGGAGTTCGAGGAG TCTAGGGCGACGAGGATG
Glut4 (Slc2a4) TCGGGGCATACACACATACA TGAAAGGTCGAAGAGGAGGG
Genomic Ppargc1α GAGTGACAGCCCAGCCTAC TCCACTCTGACACACAGCAC
DNA H19 ATAAGGGTCATGGGGTGGT GGCATCGTCTGTCCATTTAG
FoxO1 AAAATACCCCACCGCCCC GCCGAAGCAGCCAATGAAC
Gfpt1α AACATTCCCTTCCTCCTCCT CCAGCATCCGCTTTAGGTTC
Ins2 TGGCCATCTGCTGACCTAC GACCAAAGCACCTCCTCTCT
β-Actin ATGCTGACCCTCATCCACTT  AATAGCCTCCGCCCTTGT
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3.13  Statistical Analysis  
Data are presented as mean ± standard error.  Densitometry analysis was performed on 
western blot images using Kodak 1D 3.6 software (Eastman Kodak, NY, USA).  Gene 
expression, methylation density, and statistical outliers (interquartile range) were calculated 
using Microsoft Excel.  All project data was grouped and organized within Microsoft Excel and 
subsequently transferred to Graphpad Prism for statistical analysis (version 5.00, CA, USA; 
www.graphpad.com).  Statistical significance of data were determined using unpaired two-tailed 
student’s t-test or repeated measures one-way ANOVA followed by Bonferroni’s Multiple-
Comparison post-hoc test.  All calculations were performed with a 95% confidence interval. 
Statistical test used for each data set is indicated in the respective figure legend. 
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4.0 Presentation of Findings 
 
4.1  Body Weight and Adiposity 
Body weight and composition were measured each week in fathers and offspring.  As 
expected, fathers assigned to a high-fat diet were seen to weigh significantly more than both CF 
and EF at the 12-week time point (p<0.001).  Additional findings from MRI body composition 
testing revealed the FF group had a tremendously higher fat content than other fathers (p<0.001; 
n=5).  Furthermore, CF were found to have a higher total body weight, as well as higher fat 
percent, than the EF (p<0.01; n=9).   
 Statistical differences among offspring were only observed between those groups 
challenged with a high fat diet.  Interestingly, the diet challenged EFO seemed to suffer the 
greatest insult from consuming a high calorie diet.  At the 12-week time point following diet 
assignment, EFO were found to weigh significantly more than both CFO and FFO (p<0.01).  
Furthermore, EFO had significantly higher fat content than diet challenged CFO and FFO 
(p<0.001 and p<0.0001 respectively).   
 These findings indicate that fathers consuming a high fat diet became obese, while those 
assigned to a 10% control diet didn’t.  Furthermore, EFO seem to be the most susceptible to 
metabolic dysfunction compared to other offspring challenged by a high fat diet.  These results 
indicate potential epigenetic programming by fathers, which prepares the metabolism of 
offspring to live a lifestyle similar to their own.   
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Figure 8.  Father’s (F0) body weight and fat mass.  A – total body weight measured 12 
weeks after time of experimental group assignment (n= 9).  B – Total fat mass measured by 
MRI (n=5).    C – Weekly measures of paternal body weight (n=5).  Significance calculated 
by one-way ANOVA with post-hoc Bonferroni ***p<0.001 *p<0.05.  
 
 
A B 
C 
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Figure 9.  Offspring (F1) body weight and fat mass.  Solid colors represent offspring 
consuming 10% fat control diet, while striped bars are diet-challenged offspring, 
consuming a 60% high-fat diet.  A – Total body weight measured 12 weeks after time of 
diet assignment (10%-CFO/EFO/FFO n=9/13/9 respectively // 60%-CFO/EFO/FFO 
n=10/11/7 respectively).  B – Total fat mass measured by MRI (10%-CFO/EFO/FFO 
n=8/12/9 respectively // 60%-CFO/EFO/FFO n=11/11/8 respectively).  Significance 
calculated by one-way ANOVA with post-hoc Bonferroni ****p<0.0001 **p<0.005 *p<0.05. 
 
A 
B 
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4.2  Metabolic Profiling 
 Metabolic profiles for mice were assessed using computer automated indirect calorimetry 
(i.e. metabolic cages).  This well validated methodology encompasses both physiological and 
behavioral elements of data collection, which in the current study provided substantiating 
support for molecular analysis [
101
].  Together these data present for a more comprehensive 
assessment.  Moreover, for a number of reasons only male offspring in the F1 generation were 
examined.  The primary justification for excluding female offspring stemmed from their high 
rate of variability.  Furthermore, preliminary comparisons revealed distinctly different trends in 
the data collected from male and female offspring. These gender-based disparities were 
determined to be confounding variables that would compromise the validity of the study as a 
whole. 
 
4.2.1 Energy Expenditure 
 In the current study, energy expenditure was investigated to characterize the acute and 
potentially transgenerational effects had by diet and exercise on the metabolic performance of 
male offspring.  By evaluating the energy metabolism in physically active mice, as well as those 
subjected to diet-induced obesity, valuable insight was gained as to whether the onset of obesity 
was a problem that occurred from excess energy intake or a problem caused by reduced energy 
expenditure.  
 Calculations were made using whole body weight rather than lean mass due to higher 
variability using the latter (both methods reflected same trend). Findings presented here 
demonstrate that high-fat diet fathers (FF) in the founder generation experienced a significant 
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reduction in total energy expenditure compared to both exercising fathers (EF), as well as 
control fathers (CF; p<0.0001; figure 10A).  Although much less pronounced the same trend 
was observed at the 0-week time point for high-fat father offspring (FFO; figure 10B) and 
exercise-father offspring (EFO), which both exhibited reduced energy expenditure in 
comparison to control father offspring (CFO). 
  Finally, at 12-weeks the EFO who were challenged with a high-fat diet (60% energy 
derived from fat) were seen to exhibit a marked decrease in energy expenditure compared to 
CFOs also challenged by with a high fat diet (HFD).  Other data compared from the 12-week 
time point failed to produce any additional findings with statistical value. 
 As the following sections will further demonstrate, these findings here show that failure 
to thrive is most evident in EFO challenged with a HFD.  This is the first piece of evidence 
offered to hint at an unknown mechanism of phenotypic programming, which prepares 
offspring for living conditions similar to those lived by their respective father.  
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Figure 10.   Energy expenditure measured by indirect calorimetry using total body weight.  
A – Fathers (F0) energy expenditure measured 12 weeks after experimental group 
assignment (CF/EF/FF n=26/23/24 respectively).  B – Offspring (F1) energy expenditure 
measured at the 0-week time point with respect to time of diet assignment (CFO/EFO/FFO 
n=6/6/5 respectively).   C – 60 % Diet challenged offspring (F1) energy expenditure 
measured at 12 weeks with respect to time of diet assignment (60% CFO/EFO/FFO n=8).  
Significance calculated by one-way ANOVA with post-hoc Bonferroni ***p<0.001 *p<0.05. 
A 
B 
C 
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4.2.2 Activity 
  Mice activity was monitored for a duration of 72 hours, during which time ambulatory 
movements were continuously recorded on each plane of orientation (x, y, and z).  These data 
reflect the total number of breaks that occurred between the IR emitter and the IR detector.  
Findings presented are for total activity, which was the combined count of beam breaks in each 
plane.  At the 12-week period, a significant increase in total activity was seen to occur in EF, 
which had not been observed previously during time spent in metabolic cages.  The markedly 
increased level of locomotion in EF (n=27) was statistically higher than both FF (p<0.00001; 
n=29) as well as CF (p<0.001; n=29).  CFs were additionally found to be more active than FF 
(p<0.0001).  As stated, no statistical value is seen in a separate comparison of z- oriented motion, 
however these data are provided for their inference value associated with food and water 
consumption discussed later.  
 Similar observations were noted in offspring consuming a 10% fat diet.  At the 0-week 
time point both EFO (n=12) and CFO (n=10) were found to be significantly more active than 
FFO (n=12; p<0.001, p<0.01 respectively).  These findings between EFO and FFO were again 
repeated at the 12-week period (p<0.01), however no other statistically significant observations 
were made.   
 Additionally, as seen in Figure-11C, offspring challenged by a HFD were also included for 
presentation.  Despite there being no statistical difference, the trend shaping between diet-
challenged EFO and FFO is indicative of epigenetic modifications that alter their susceptibilities 
to metabolic impairment.   
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Figure 11.  Total activity measured during indirect calorimetry (x+y+z axes).  A – Father’s 
(F0) total activity measured at 12 weeks (CF/EF/FF n=29/27/29 respectively).  B – Offspring 
total activity measured at 0 weeks with respect to time of diet assignment (CFO/EFO/FFO 
n=10/12/12).  C – Total activity of 10% diet offspring (solid) and 60% diet challenged 
offspring (striped) measured at 12 weeks (10% CFO/EFO/FFO n=8/9/8 respectively // 60% 
CFO/EFO/FFO n=8/8/8).  Significance calculated by one-way ANOVA with post-hoc 
Bonferroni ****p<0.0001 ***p<0.001 **p<0.005 *p<0.05. 
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4.2.3  Food and Water Consumption 
 In addition to energy expenditure and motor activity, both food and water consumption 
were also recorded during the time spent housed in metabolic cages.  To ensure precision and 
accuracy of these data, food and water sensors were calibrated between each use of the system.  
Furthermore, cages were inspected daily and notations were made when appropriate to disband 
any data discrepancies associated to animals that had tendencies to play with their chow rather 
than eat.   
 Among fathers, the only statistical differences identified occurred at the 12-week time 
period.  Surprisingly, FFs (n=12) were found to consume substantially less chow than both CF 
(p<0.01; n=13) and EF (p<0.0001; n=10).  However, it is important to note that these data for 
fathers were also evaluated with respect to caloric values (figure 12b) and although no statistical 
significance was found FFs did consume more calories on average than both CF and EF (7.88% 
and 9.65%, respectively).  
 Statistically relevant findings between groups of offspring were noted at both 0- and 12-
week time points for food and water consumption.  Food consumption at 0-weeks was found to 
relatively similar across groups; FFO (n=9), however, appeared to drink an excessive amount of 
water (p<0.01). 
 Several disparities between offspring were also found at 12-weeks.   The most notable of 
which includes the excessive amount of water FFO drank compared to CFO and EFO 
(p<0.0001).  FFO also consumed substantially more food than EFO (p<0.01).    
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 These findings, measured in FFO, are suggestive of what could reasonably be inferred as 
polydipsia (excessive thirst), a hallmark symptom commonly seen among newly diagnosed type 
2 diabetic patients. [
102
]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Father’s (F0) food (A), calories (B), and water (C) consumption measured at 12 
weeks, with respect to time of experimental group assignment (CF/EF/FF n=14/12/14 
respectively).  Significance calculated by one-way ANOVA with post-hoc Bonferroni 
***p<0.001 *p<0.05. 
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Figure 13.   Offspring (F1) food (A) and water (B) consumption measured at 0 weeks, with 
respect to time of diet assignment (CFO/EFO/FFO n=9/11/8 respectively).  Significance 
calculated by one-way ANOVA with post-hoc Bonferroni *p<0.05. 
 
 
 
 
 
 
 
 
 
Figure 14.  10% Diet offspring (F1) food (A) and water (B) consumption measured at 12 
weeks, with respect to time of diet assignment (A- CFO/EFO/FFO n=8/9/8 respectively // B 
– 7/9/7 respectively).  Significance calculated by one-way ANOVA with post-hoc Bonferroni 
***p<0.001 *p<0.05. 
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 4.3  Glucose Tolerance Test and Plasma Insulin 
 Glucose tolerance testing (GTT) was performed to gain a temporal perspective on 
glucose metabolism between different groups of animals.   Fathers consuming a high-fat diet 
were found to have a statistically higher area under the curve (AUC) than CF (n=6) and EF 
(p<0.001; n=5).  Furthermore, 12-week insulin concentrations measured in fathers reveal FFs 
(n=10) became hyperinsulinemic as a result of consuming a high fat diet.  Basal insulin, as well 
as acute phase response insulin (APR; 30 minutes) measured in FFs was significantly higher than 
CF and EF fathers (p<0.0001; n=7 and 10 respectively).  Taken together, these findings indicate 
FFs had developed a diabetic phenotype in response to a high-fat diet. 
 Analyses performed on offspring GTT data at 0 and 12-weeks revealed a 
significantly higher AUC in FFO compared to CFO and EFO (p<0.01; n=30, 30, 40 
respectively).  Findings at week 12 revealed the same trend, as seen by a significantly higher 
AUC measured in FFO compared to CFO and EFO (p<0.001; n=9, 6, 9 respectively).  All other 
data collected on offspring, who were consuming a normal control diet, were found to be non-
significant.  
 Furthermore, plasma insulin measured in diet challenged EFO demonstrated, once again, 
appeared to be most affected by the high fat content.  Although basal insulin measures were 
statistically insignificant between groups, the concentrations seen in EFO (n=8) appeared higher 
than all other offspring.  Insulin measures at the 30-minute APR, however, were found to be 
statistically significant compared to both CFO and FFO (p<0.01 and p<0.001 respectively; n=6). 
 These results demonstrate that FFs developed a diabetic phenotype (i.e. hyperglycemic, 
hyperinsulinemic) and, to a lesser extent, so did their respective offspring despite the fact they 
61 
 
were consuming a regular control diet.  Moreover, diet challenged EFO were again seen to be the 
most susceptible to the deleterious effects of a HFD; further substantiating paternal-of-origin 
transgenerational programming.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15.  Father’s (F0) glucose (A) and plasma insulin (B) measured at week 12, with 
respect to time of diet assignment (A – CF/EF/FF n=6/5/6 // B – n=7/6/7 respectively).  
Significance calculated by two-tailed student’s t-test ****p<0.0001 ***p<0.001 **p<0.005 
*p<0.05. 
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Figure 16.  Control diet offspring (F1) glucose measured at 0 weeks (A – 10% 
CFO/EFO/FFO n=33/35/28) and 12 weeks (B – 10% CFO/EFO/FFO n=35/40/30).               
C – Plasma insulin measured in 60% high-fat diet challenged offspring at week 12 (60% 
CFO/EFO/FFO n=6/7/6 respectively).  Significance calculated by two-tailed student’s t-test 
****p<0.0001 ***p<0.001 **p<0.005  *p<0.05. 
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4.4  Developmental Monitoring 
 Analyses of developmental milestones revealed several intriguing differences among 
groups of offspring (male and female). One of the most notable disparities was seen in the body 
weights recorded on post-natal day 7 (Figure 17B)  Offspring born from fat-diet fathers (FFO) 
were found to have a significantly lower body weight compared to both control father offspring 
and exercise father offspring (-10.7% and -13.1% respectively).  This curious observation is one 
also described in several human studies, which identified a powerful correlation between low 
birth weight and paternal diabetes [
10,62,103-105
] 
 In addition to reduced body weights, FFO appeared developmentally delayed in the time 
at which their eyes first opened, fur appeared, and upper/lower incisors erupted.  
 Taken together these findings effectively illustrate that paternal diet and exercise play an 
important role in shaping their progeny’s intrauterine development.  
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Figure 17.  Developmental measurements taken on post-natal day 7.  Observations made 
here did not distinguish between male and female offspring.   A - Presentation of all 
parameters measured, normalized against control offspring.  B – Offspring (F1) weight as 
measured on post-natal day 7. Sample size: CFO/EFO/FFO n=49/42/31 respectively.  
Significance calculated by one-way ANOVA with post-hoc Bonferroni **p<0.005 *p<0.05. 
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4.5  F0 Protein Expression  
 OGT and OGA protein expressions were quantified from western blot band intensities.  
Only father’s data are presented here, due to offspring data being unavailable at the time of 
discussion.  However, one implication of these data that is crucial to recognize is they effectively 
demonstrate OGT and OGA protein expressions are highly correlative to mRNA levels measured 
by PCR. 
 Protein expression measured in muscle revealed that FFs (n=3) have significantly higher 
levels of OGT compared to both CF and EF (p<0.01; n=2 and p<0.005; n=3 respectively).  
Furthermore, FFs were found to have significantly less OGA compared to CF (p<0.01), while 
EF’s expression was significantly increased relative to both CF and FF (p<0.01).   
 Hepatic tissue demonstrated a similar pattern of OGT and OGA expression.  This is seen 
by a significant reduction in measurable OGT within EF compared to CF and FF (p<0.01), in 
addition to a sharp increase in the levels of OGA within EF compared to CF and FF (p<0.005).  
FFs were also found to have significantly higher OGA compared to CF (p<0.005).    
 Finally, pancreatic tissue exhibited significantly higher amounts of OGT within FF 
compared to CF (p<0.05), while EFs were found to have a marked reduction in OGT compared 
to CF and FF (p<0.005 and 0.01 respectively).  Pancreatic OGA expression was not included 
here due to inconclusive results at the time of authoring this paper.   
 These findings validate that consumption of a HFD causes an increase in OGT, which is 
an expected consequence of elevated flux through the hexosamine pathway.    
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Figure 18.  Father’s (F0) OGT and OGA total protein expression measured in insulin 
sensitive tissues.  A – OGT protein expression measured in muscle (n=3).  B – OGA protein 
expression measured in muscle (n=3).  C – OGT protein expression measured in liver 
(n=3).  D – OGA protein expression measured in liver (n=3).  E – OGT protein expression 
measured in pancreas (n=3).  Significance calculated by two-tailed student’s t-test 
***p<0.001 **p<0.005 *p<0.05. 
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4.6  Gene Expression 
 Messenger RNA (mRNA) transcripts were measured by real-time PCR to assess relative 
expression of target genes that, to varying extents, have all been implicated in an obese diabetic 
phenotype. All molecular data for offspring, presented in the subsequent sections, are for those 
animals assigned to a 10% fat control diet (i.e. no diet-challenged offspring included).  Statistical 
differences were calculated by unpaired student’s t-tests. 
 
4.6.1 Skeletal Muscle mRNA 
 Significant differences were found between several genes examined in both fathers and 
offspring gastrocnemius muscle. Just like protein expression, gene expression of uridine 
diphospho-N-acetylglucosamine:peptide β-N-acetylglucosaminyltransferase (Ogt) was found to 
be substantially higher in FFs compared to both CF and EF (p≤ 0.01; n=4).  Concomitant 
expression of Oga was identified to be statistically lower in FF compared to CF and EF (p<0.05).  
Moreover, Oga was statistically elevated in EF compared to CF (p<0.05). 
 These observations were also exhibited in FFO (n=3), where Ogt expression was found 
to be statistically higher than CFO and EFO (p<0.001; n=5).  Furthermore, expression for Oga in 
EFO was significantly higher than FFO (p<0.05).   
 The patterns of Ogt and Oga gene expression, observed here in FF and FFO, are a 
platform for excessive protein O-GlcNAcylation, which current literature would suggest is a 
possible cause of T2DM. 
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Figure 19.  Gene expressions of Ogt and Oga (mRNA) measured in muscle.  A – Father’s 
(F0) Ogt and Oga expressions (n=4).  B – Offspring (F1) Ogt and Oga expressions 
(CFO/EFO/FFO n=4/3/3 respectively).  Significance calculated by two-tailed student’s t-
test ***p<0.001 **p<0.005 *p<0.05. 
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 The imprinting genes H19 and Igf2 also revealed interesting patterns of reciprocity in 
their expression. Although the expression for H19 in fathers was not quantified as significant, the 
trend remains interesting nonetheless.  However, a comparison of the monoallelic expression for 
Igf2 revealed EF and FF are drastically higher than CF (p<0.001 and 0.01 respectively).  
Furthermore, EF appeared statistically higher than FF (p<0.05).  While in offspring, the 
expression for H19 in EFO (n=5) was discovered to be drastically lower than CFO and FFO 
(p<0.0001 and 0.0005 respectively; n=4) 
 Igf2 expressions among offspring were highest in EFO (p<0.05).  Interestingly, the trends 
seen in Figures 20A and 20B illustrates there is almost perfect chirality between fathers H19 and 
offspring Igf2.  The epigenetic mechanisms responsible for this phenomenon will be further 
explained in the methylation results.  
 
 
Figure 20.  Gene expressions of H19 and Igf2 (mRNA) measured in muscle.  A – Father’s 
(F0) H19 and Igf2 expressions (CF/EF/FF n=3/4/4 respectively).  B – Offspring (F1) H19 and 
Igf2 expressions (CFO/EFO/FFO n=3/4/4 respectively).  Significance calculated by two-
tailed student’s t-test ****p<0.0001 ***p<0.001 **p<0.005 *p<0.05. 
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Other genes examined include Slc2A4 (Glut4), Ptpn1, and Pdk4.  In fathers, Glut4 was 
found to be statistically higher in EF compared to FF (p<0.01); a trend that was further seen in 
EFO where expression was significantly higher compared to CFO and FFO (p<0.01).  
Overexpression of Glut4 indicates potential for improved glucose sensitivity, although to 
confirm such a prediction necessitates protein expression and activity also be investigated, which 
is the case for each of the genes examined here. 
 
 
 
 
 
 
 
Figure 21. Gene expression for Glut4 (mRNA) measured in muscle.  A – Father’s (F0) 
expression (CF/EF/FF n=5/3/3 respectively).  B – Offspring (F1) expression 
(CFO/EFO/FFO n=4/6/4 respectively).  Significance calculated by two-tailed student’s t-
test **p<0.005. 
 
 
 
A B 
71 
 
Ptpn1, which encodes the insulin receptor antagonist PTP1B, was observed to be 
statistically higher in FF compared to CF and EF (p<0.005 and p<0.01 respectively).  FFO were 
also seen to be statistically higher than EFO and CFO (p<0.005 and p<0.05 respectively), in 
addition to CFO expression also being statistically higher than EFO (p<0.01).  These findings 
indicate FF and FFO (assigned to a normal control diet) have a much higher risk of becoming 
insulin resistant compared to other groups of mice.     
 Finally, Pdk4 expression in FF muscle was found to be statistically higher than both CF 
and EF (p<0.005).  Among offspring, Pdk4 transcripts measured in FFO were identified as 
statistically increased compared to EFO (p<0.05), which again is indicative of a diabetic 
phenotype. 
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Figure 22. Gene expression for Ptpn1 (mRNA) measured in muscle.  A – Father’s (F0) 
expression (CF/EF/FF n=5/3/3 respectively).  B – Offspring (F1) expression 
(CFO/EFO/FFO n=4/6/4 respectively).  Significance calculated by two-tailed student’s t-
test ***p<0.001 **p<0.005 *p<0.05. 
 
 
 
 
 
 
Figure 23. Gene expression for Pdk4 (mRNA) measured in muscle.  A – Father’s (F0) 
expression (CF/EF/FF n=5/3/3 respectively).  B – Offspring (F1) expression 
(CFO/EFO/FFO n=4/6/4 respectively).  Significance calculated by two-tailed student’s t-
test **p<0.005 *p<0.05. 
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4.6.2 Pancreatic mRNA 
 In fathers the trends between Ogt and Oga were similar to the results presented for 
muscle.  Ogt expression in FF was statistically elevated compared to CF and EF (p<0.005), while 
for Oga EF had the highest expression to both CF and FF (p<0.005).   These patterns of 
expression were further carried over to offspring, where Ogt was highest in FFO compared to 
CFO and EFO.  In addition, EFO and CFO were demonstrated significantly higher than FFO 
(p<0.05).   These findings were also observed in skeletal muscle, and again are reflective of 
T2DM.  
 
 
Figure 24.  Gene expressions of Ogt and Oga (mRNA) measured in the pancreas.  A – 
Father’s (F0) Ogt and Oga expressions (n=4).  B – Offspring (F1) Ogt and Oga expressions 
(CFO/EFO/FFO n=4/3/3 respectively).  Significance calculated by two-tailed student’s t-
test **p<0.005 *p<0.05. 
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In fathers, there was no significant difference identified between CF and EF H19, however 
FF were found to be significantly higher than both father groups (p<0.005).  Moreover, an 
increase in Igf2 gene expression within EF was found to be statistically significant compared to 
FF (p<0.05).  
In offspring, H19 expression in EFO was statistically higher compared to CFO and FFO 
(p<0.005).  Expression of H19 measured in CFO was additionally found to be higher than that of 
FFO (p<0.05).  These results contradict findings seen in other tissues.  However, this is likely the 
product of methylation patterns within H19’s 5’ DMICR (discussed in the following section).  
The developmental programming of H19 and Igf2, experienced by FF offspring, is likely to 
promote an enlargement of the pancreas.   This is perhaps a preparatory mechanism, conferred 
by their respective fathers to facilitate increased insulin production.  These findings are yet 
another example of paternal programming, preparing offspring for a similar life style. 
 
Figure 25.  Gene expressions of H19 and Igf2 (mRNA) measured in the pancreas.  A – 
Father’s (F0) H19 and Igf2 expressions (CF/EF/FF n=3/4/4 respectively).  B – Offspring (F1) 
H19 and Igf2 expressions (CFO/EFO/FFO n=3/4/4 respectively).  Significance calculated by 
two-tailed student’s t-test ***p<0.001 **p<0.005 *p<0.05. 
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 Analysis of gene expression in fathers further revealed Glut4 was statistically elevated in 
EF compared to CF and FF (p<0.0005).  Additionally, differences between CF and FF were 
found to be statistically relevant (p<0.0005).   Interestingly, this shortage of Glut4 in FF was 
reversed in FFO, who were shown to have statistically higher levels than CFO (p<0.05).  These 
findings indicate a severe deficit in glucose sensitivity occurring in FF pancreatic tissue 
 Pdk4 expressions in fathers and offspring were highly similar to one another.  FFs were 
found to have significantly higher levels of Pdk4 mRNA compared to CF and EF (p<0.05).  In 
addition, expression measured in CF was statistically higher than EF (p<0.05).  In offspring, 
EFO had significantly lower levels of Pdk4 transcript compared to CFO and FFO (p<0.0005 and 
0.001 respectively).    
 Similar to Pdk4, the expression of FoxO1 between fathers and offspring were highly 
similar.  FFs were shown to have the highest level of expression compared to CF and EF 
(p<0.001), while CF was even lower than EF (0.005).  Although the trend in offspring was not as 
pronounced as in fathers, FFO were found to have a significantly higher amount of FoxO1 
transcript compared to CFO (p<0.05).   
 Finally, Ptpn1 was not differentially expressed in fathers, however in FFO its 
transcriptional activity was significantly higher than that measured in CFO (p<0.05). 
 The findings presented here demonstrate that FFO experienced the same detrimental 
trends observed within the skeletal muscle tissue.  One notable difference, however, was the 
substantial increase of Igf2 expression in FFO.  This only occurred in pancreatic tissue, 
indicating perhaps that FFO were epigenetically programmed by their fathers to have a higher 
capacity for insulin production.  
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Figure 26. Gene expression for Glut4 (mRNA) measured in the pancreas.  A – Father’s (F0) 
expression (CF/EF/FF n=3/3/4 respectively).  B – Offspring (F1) expression 
(CFO/EFO/FFO n=3/3/3 respectively).  Significance calculated by two-tailed student’s t-
test ***p<0.001 *p<0.05. 
 
 
 
 
 
 
 
Figure 27.  Gene expression for Pdk4 (mRNA) measured in the pancreas.  A – Father’s (F0) 
expression (CF/EF/FF n=3/3/3 respectively).  B – Offspring (F1) expression 
(CFO/EFO/FFO n=3/3/3 respectively).  Significance calculated by two-tailed student’s t-
test ***p<0.001 **p<0.005 *p<0.05. 
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Figure 28.  Gene expression for FoxO1 (mRNA) measured in the pancreas.  A – Father’s 
(F0) expression (CF/EF/FF n=3/3/3 respectively).  B – Offspring (F1) expression 
(CFO/EFO/FFO n=4/3/3 respectively).  Significance calculated by two-tailed student’s t-
test ***p<0.001 *p<0.05. 
 
 
 
 
 
 
Figure 29.  Gene expression for Ptpn1 (mRNA) measured in the pancreas of offspring (F1) 
(CFO/EFO/FFO n=3/3/4 respectively).  Significance calculated by two-tailed student’s t-
test *p<0.05. 
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4.6.3  Hepatic mRNA 
 In hepatic tissue collected from fathers, the FF group had significantly elevated 
expression for Ogt compared to CF and EF (p<0.05 and 0.01), while their respective level of Oga 
was found to be statistically lower than EF (p<0.05).  This pattern was repeated to a lesser extent 
among offspring, where EFO showed lower levels of Ogt mRNA compared to CFO (p<0.05), 
and additionally were seen to have the highest level of Oga expression compared to CFO and 
FFO (p<0.05 and 0.01).  CFO were additionally found to have higher Oga expression compared 
to FFO (p<0.01). 
   
Figure 30.  Gene expressions of Ogt and Oga (mRNA) measured in the liver.  A – Father’s 
(F0) Ogt (CF/EF/FF n=5/4/4) and Oga expressions (CF/EF/FF n=4/3/4 respectively).  B – 
Offspring (F1) Ogt and Oga expressions (CFO/EFO/FFO n=5/4/4 respectively).  
Significance calculated by two-tailed student’s t-test **p<0.005 *p<0.05. 
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Figure 31.  Gene expressions of H19 and Igf2 (mRNA) measured in the liver.  A – Father’s 
(F0) H19 and Igf2 expressions (CF/EF/FF n=5/4/4).  B – Offspring (F1) H19 and Igf2 
expressions (CFO/EFO/FFO n=3/3/3 respectively).  Significance calculated by two-tailed 
student’s t-test **p<0.005 *p<0.05. 
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 Differential gene expression was seen to occur in several additional genes including 
Glut4 (an isoform typically only assessed in skeletal muscle), where EF showed the greatest 
level of expression compared to CF and FF (p<0.005).  Strangely, these findings were observed 
in reverse among offspring, where EFO had a statistically lower amount of Glut4 mRNA 
compared to CFO and FFO (p<0.05).   
 Ptpn1 gene product was highest in FF, compared to both CF and EF (p<0.05).  This 
observation was also seen to a lesser degree in offspring, where FFO were shown to have 
statistically higher levels of Ptpn1 transcript compared to CFO (p<0.05). 
 Finally, Pdk4 gene expression was found highly conserved from fathers to offspring.  
Measurements from EFs were significantly lower than CF and FF (p<0.01 and 0.05), while 
among offspring groups FFO were observed to be significantly higher than both CFO and EFO 
(p=0.0001 and p<0.0001 respectively).   
 
 
 
 
 
 
Figure 32.  Gene expression for Glut4 (mRNA) measured in the liver.  A – Father’s (F0) 
expression (CF/EF/FF n=3/4/3 respectively).  B – Offspring (F1) expression 
(CFO/EFO/FFO n=3/3/3 respectively).  Significance calculated by two-tailed student’s t-
test ***p<0.001 *p<0.05. 
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Figure 33.  Gene expression for Ptpn1 (mRNA) measured in the liver.  A – Father’s (F0) 
expression (CF/EF/FF n=4/4/4 respectively).  B – Offspring (F1) expression 
(CFO/EFO/FFO n=5/4/4 respectively).  Significance calculated by two-tailed student’s t-
test *p<0.05. 
 
 
 
 
 
 
 
Figure 34. Gene expression for Pdk4 (mRNA) measured in the liver.  A – Father’s (F0) 
expression (CF/EF/FF n=5/4/3 respectively).  B – Offspring (F1) expression 
(CFO/EFO/FFO n=5/5/4 respectively).  Significance calculated by two-tailed student’s t-
test ****p<0.0001 ***p<0.001 **p<0.005 *p<0.05. 
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4.7 Methylation Analysis 
Epigenetic programming was assessed in terms of the methylation patterns occurring at 
gene promoters, which were conserved from fathers to offspring.  Several differences were 
observed between animals, although the most interesting findings were the seemingly opposite 
trends in methylation observed between exercising fathers and high-fat diet fathers, as well as 
their respective offspring.    
4.7.1  Muscle  
  As seen in figures 35 and 36 significant differences were identified for Ogt and Oga 
methylation in fathers and offspring.  EFs were found to have a drastically higher level of 
methylation at Ogt compared to FF (p<0.01), while FF were significantly more methylated on 
Oga relative to CF and EF.  The changes witnessed among fathers were found well maintained in 
the F1 generation.  Specifically, EFO had higher levels of methylation than CFO and FFO 
(p<0.05) for Ogt, while Oga was seen to be hypomethylated with respect to CFO and FFO 
(p<0.01).  
  Additionally, H19 methylation for fathers and offspring was demonstrated to be 
remarkably similar.  EF showed elevated methylated at the H19 5’ DMICR compared to CF and 
FF (p<0.005 and 0.01 respectively).  Furthermore, CFs were also seen to have higher 
methylation compared to FF (p<0.01).   
  Investigation of Pdk4 revealed a significant reduction in the methylation within FF 
compared to CF and EF (p<0.005), while in offspring EFO demonstrated to be significantly 
higher than CFO and FFO (p<0.01 and p<0.05).   
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Glut4 methylation among fathers was found to be lowest in EF compared to CF and FF 
(p<0.01 and p<0.0001).  Additionally, FFs demonstrated a statistically significant increase in 
methylation relative to CF (p<0.05).  In offspring, strangely there was a reversal in Glut4 
methylation compared to their respective fathers.  FFO showed minimal methylation that was 
significantly lower than CFO (p<0.01), while EFO were additionally seen to be statistically 
higher than both FFO as well as CFO (p<0.01 and 0.05 respectively). 
Finally, analysis of Ptpn1 methylation in fathers revealed EFs were significantly higher 
than FF (p<0.05), while in offspring EFO demonstrated an increase in methylation in comparison 
to both CFO and FFO (p<0.01 and 0.001 respectively). 
The validity of these findings are further substantiated by the respective gene expressions 
described previously, where methylation is clearly shown to represses gene transcription.  The 
only exception appears with the gene Glut4, where offspring’s expression and methylation 
exhibit transposable trends, indicating an ulterior means of gene regulation.    
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Figure 35. Promoter methylation for Ogt (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Ogt methylation (CF/EF/FF n=3/3/4 respectively).  B – Offspring (F1) Ogt 
methylation (CFO/EFO/FFO n=4/4/3 respectively).  Significance calculated by two-tailed 
student’s t-test **p<0.005 *p<0.05. 
 
 
 
 
 
  
 
Figure 36.  Promoter methylation for Oga (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Oga methylation (CF/EF/FF n=3/3/4 respectively).  B – Offspring (F1) Oga 
methylation (CFO/EFO/FFO n=4/4/3 respectively).  Significance calculated by two-tailed 
student’s t-test **p<0.005 *p<0.05. 
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Figure 37.   Promoter methylation for H19 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) H19 methylation (n=3).  B – Offspring (F1) H19 methylation (n=4).  
Significance calculated by two-tailed student’s t-test ***p<0.001 **p<0.005 *p<0.05. 
 
 
 
 
 
 
Figure 38. Promoter methylation for Pdk4 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Pdk4 methylation (CF/EF/FF n=3/3/4 respectively).  B – Offspring (F1) Pdk4 
methylation (CFO/EFO/FFO n=4/4/3 respectively).  Significance calculated by two-tailed 
student’s t-test **p<0.005 *p<0.05. 
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Figure 39.  Promoter methylation for Glut4 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Glut4 methylation (CF/EF/FF n=3/4/4 respectively).  B – Offspring (F1) Glut4 
methylation (CFO/EFO/FFO n=4/4/3 respectively).  Significance calculated by two-tailed 
student’s t-test ****p<0.0001 **p<0.005 *p<0.05. 
 
 
 
 
 
 
 
Figure 40.  Promoter methylation for Ptpn1 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Ptpn1 methylation (CF/EF/FF n=2/4/3 respectively).  B – Offspring (F1) Ptpn1 
methylation (n=4).  Significance calculated by two-tailed student’s t-test ***p<0.001 
**p<0.005 *p<0.05. 
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4.7.2  Pancreas  
Promoter-methylation of several genes examined in the pancreas were discovered to be 
conserved from fathers to offspring.  Analysis with an unpaired student’s t-test revealed the 
methylation of Ogt in fathers was statistically higher in EF compared to FF (p<0.01).  Strangely, 
in fathers only negligible amounts of Oga were identified.  In offspring, Ogt methylation was 
statistically reduced in FFO compared to CFO (p<0.05).  Oga methylation was found to be lower 
in EFO compared to both CFO and FFO (p<0.05 and 0.01 respectively).  
 
 
 
 
 
 
 
 
 
Figure 41. Promoter methylation for Ogt and Oga (genomic DNA) measured in the muscle.  
A – Father’s (F0) Ogt methylation (n=2); Father’s Oga methylation was negligible.  B – 
Offspring (F1) Ogt methylation (CFO/EFO/FFO n=4/3/4 respectively).  C – Offspring (F1) 
Oga methylation (CFO/EFO/FFO n=3/4/4 respectively).  Significance calculated by two-
tailed student’s t-test **p<0.005 *p<0.05. 
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 Methylation of H19 in FF was statistically higher than both CF and EF (p<0.05).  This 
trend was carried to offspring, where FFO were demonstrated statistically increased compared to 
EFO (p<0.05).   
 
 
 
 
 
 
 
Figure 42. Promoter methylation for H19 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) H19 methylation (n=2).  B – Offspring (F1) H19 methylation (CFO/EFO/FFO 
n=3/4/3 respectively). Significance calculated by two-tailed student’s t-test *p<0.05. 
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Examination of Pdk4’s promoter region within pancreatic tissue revealed FFs were in a 
hypomethylated state compared to CF and EF (p<0.01).  This was also seen among offspring, 
where FFO were highly similar to their hypomethylated fathers and were statistically lower than 
CFO and EFO (p<0.01 and 0.005).  Furthermore, EFO were statistically higher than CFO 
(p<0.005).   
Glut4 was found statistically reduced in FF compared to EF (p<0.01), while in offspring 
the FFO group was also statistically lower than EFO in addition to CFO (p<0.005).  EFO also 
exhibited significantly less methylation compared to CFO (p<0.01).  
Lastly, although no statistical differences were found to exist in Ptpn1 between fathers, 
FFO methylation was found significantly reduced compared to CFO and EFO (p<0.005), while 
EFO was additionally less than CFO (p<0.01). 
 
 
 
 
 
 
Figure 43.   Promoter methylation for Pdk4 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Pdk4 methylation (n=2).  B – Offspring (F1) Pdk4 methylation (n=3). 
Significance calculated by two-tailed student’s t-test ***p<0.001 **p<0.005. 
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Figure 44. Promoter methylation for Glut4 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Glut4 methylation (n=2).  B – Offspring (F1) Glut4 methylation 
(CFO/EFO/FFO n=3/4/3 respectively). Significance calculated by two-tailed student’s t-test 
***p<0.001 **p<0.005. 
 
 
 
 
 
  
Figure 45.  Promoter methylation for Ptpn1 in offspring (F1) (n=3). Significance calculated 
by two-tailed student’s t-test ***p<0.001 **p<0.005. 
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4.7.3  Liver 
  Examination of hepatic Ogt in fathers revealed significantly higher methylation occurring 
in EF compared to FF (p<0.01).  Ogt’s counterpart, Oga, was significantly more methylated in FF 
compared to CF and EF (p<0.05 and 0.01 respectively).  Furthermore, EF exhibited a statistical 
reduction in methylation compared to CF (p<0.05).  The exact same results were found in 
offspring Ogt, as well as Oga.  The only exception however was the power of significance 
calculated for Oga in offspring, which was found to be p<0.005 for all comparisons described for 
fathers.  
     
 
 
Figure 46.  Promoter methylation for Ogt (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Ogt methylation (n=3).  B – Offspring (F1) Ogt methylation (CFO/EFO/FFO 
n=4/3/3 respectively). Significance calculated by two-tailed student’s t-test **p<0.005. 
 
  
 
 
 
Figure 47.  Promoter methylation for Oga (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Oga methylation (n=3).  B – Offspring (F1) Oga methylation (n=4). 
Significance calculated by two-tailed student’s t-test ***p<0.001 **p<0.005 *p<0.05. 
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H19 in fathers and offspring was nearly identical, with the only differences lying in the 
power of statistical significance.  In fathers, EFs were hypermethylated compared to CF and FF 
(p<0.001 and 0.0001 respectively).  Additional significance was found upon comparison of CF 
and FF, where FFs were again less methylated (p<0.01).  In offspring, these same trends were 
reported, however the powers of significance were p<0.001, 0.01, and 0.01 respectively. 
   Analyses made on Pdk4 methylation demonstrated FF to be hypomethylated compared 
to CF and EF (p<0.01), while findings among offspring were the same, with FFO exhibited the 
smallest level of methylation.   
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Figure 48.   Promoter methylation for H19 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) H19 methylation (CF/EF/FF n=2/4/3 respectively).  B – Offspring (F1) H19 
methylation (CFO/EFO/FFO n=4/3/3 respectively). Significance calculated by two-tailed 
student’s t-test ***p<0.001 **p<0.005 *p<0.05. 
 
 
 
 
 
 
 
Figure 49.  Promoter methylation for Pdk4 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Pdk4 methylation (CF/EF/FF n=3/4/3 respectively).  B – Offspring (F1) Pdk4 
methylation (CFO/EFO/FFO n=4/3/4 respectively). Significance calculated by two-tailed 
student’s t-test **p<0.005. 
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Glut4 methylation among fathers appeared lowest in FF (p<0.005 and 0.01).  In 
offspring, the FFO group was found to be less methylated compared to CFO and EFO (p<0.005), 
and furthermore EFO was statistically higher than CFO (p<0.05). 
 Ptpn1 methylation patterns between fathers and offspring were remarkably similar to one 
another, with EF/EFO appearing statistically higher than FF/FFO (p<0.05).  
Taken together, findings these are indicative of methylation-based transgenerational 
programming.  This is evident by methylation patterns, which were highly conserved from 
fathers to offspring in several genes including Ogt, Oga, Pdk4, Ptpn1, and H19.  Furthermore, 
these trends complemented respective gene expressions.  
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Figure 50.  Promoter methylation for Pdk4 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Pdk4 methylation (CF/EF/FF n=3/4/3 respectively).  B – Offspring (F1) Pdk4 
methylation (CFO/EFO/FFO n=4/3/4 respectively). Significance calculated by two-tailed 
student’s t-test ***p<0.001 **p<0.005 p<0.05. 
 
 
 
 
 
 
Figure 51.  Promoter methylation for Pdk4 (genomic DNA) measured in the muscle.  A – 
Father’s (F0) Pdk4 methylation (CF/EF/FF n=3/4/3 respectively).  B – Offspring (F1) Pdk4 
methylation (CFO/EFO/FFO n=4/3/4 respectively). Significance calculated by two-tailed 
student’s t-test *p<0.05. 
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5.0 Discussion 
 
The findings in this investigation clearly demonstrate that paternal diet and exercise are 
capable of producing epigenetic changes that subsequently alter the metabolic phenotype of male 
offspring.  These changes appear to be linked to abnormal methylation patterns occurring at 
regulatory regions of several genes examined, all of which are known to be involved in 
metabolic homeostasis.  To the best of our knowledge this is the first time paternal HFD and 
chronic exercise have been observed to cause transgenerational effects that directly modify the 
glucose and energy metabolism in male offspring within the F1 generation of mice. 
 The transgenerational detriments observed in this study, which were associated with 
paternal nutrition, first became apparent at the time when birth weights were measured.  
Offspring born to fathers consuming a HFD were found to have a substantially lower birth 
weight compared to other cohorts.  The significance of these findings are well described in 
multiple human investigations, which noted the same trend among infants born from diabetic 
(T2DM) fathers and non-diabetic mothers [
104,105, 103
].  Longitudinal studies have since followed 
thousands of these children well into adulthood to gain a better understanding of the long-term 
risks associated with birth weight [
104,105, 103
].  Common findings among these investigations 
indicate that low-birth weight is highly correlated to an increased risk for developing insulin 
resistance in young adulthood (1.8-fold increase; 1,608 children; p=0.004) [
104,105, 103
]. 
 The results gathered from gene expression analysis and indirect calorimetry demonstrate 
that long-term free wheel running in fathers led to exercise-induced transgenerational 
programming within their offspring, which was manifested as a reduction in basal energy 
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expenditure.  Therefore, when these offspring (i.e. EFO) were challenged with a high fat diet 
they were more prone to becoming obese (data not shown).  Moreover, offspring whose father’s 
consumed a HFD appeared to be epigenetically prepared for similar conditions, as seen by the 
diminished effects incurred when challenged with the same high-fat diet.  These observations 
indicate that male offspring are programmed to thrive under the same living conditions as their 
respective fathers.  Although the impacts of maternal obesity on offspring (male and female) 
have been documented in both mice and human studies alike [
9,10,39,53,54,103,104,106,107
], as far as we 
know this is the first account to document a transgenerational-based predisposition/preparedness 
existing within the father-to-son lineage. 
 As discussed in previous sections there have been several new reports by investigators 
implicating paternal ‘epimutations’, like DNA methylation, to be key players in the 
transgenerational pathogenesis of obesity and metabolic syndrome [
12,16,18,19,39,107
].  These 
allegations are well supported by findings reported here, which revealed a highly differentiated 
pattern in the methylation and gene expression between offspring sired by exercising fathers and 
those sired by fathers who consumed a HFD.  The most notable molecular-based disparity 
between these cohorts was identified in the percent methylation found in the promoter regions of 
several metabolic genes including Ogt, Oga, Ptpn1, Glut4, Pdk4, H19, and FoxO1.  Overall, 
these genes were primarily found to be hypomethylated in the male offspring born from fathers 
consuming a HFD.  Some exceptions, however, were found to occur on Oga, FoxO1, and 
pancreatic H19; all of which were seen to be hypermethylated with respect to other groups of 
offspring.  Interestingly, the genomic DNA in human (and mice) tumor cells is often found in a 
hypomethylated state [
108
].  One could speculate these findings (i.e. FFO hypomethylation) may 
be correlated not only to an increased risk for metabolic impairment, but also cancer. 
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 Although the methylation patterns observed here are indicative of transgenerational 
inheritance it is crucial to note that no screening was performed to identify DNA sequence 
mutations (e.g. point mutation; single nucleotide polymorphism).  Therefore, changes in gene 
expression cannot solely be attributed to mechanisms of epigenetic regulation.  Furthermore, it 
can only be speculated that these epigenetic changes were also present within the germ line, 
considering at the time of this discussion sperm samples had not yet been subjected to 
methylation analysis.   
 The concurrent overexpression of Ogt and under expression of Oga in insulin sensitive 
tissues is a recipe for metabolic catastrophe that was observed in all tissues examined from HFD 
fathers and their offspring (FF and FFO, respectively). Under such conditions (i.e. elevated OGT 
and/or depressed OGA) excessive O-GlcNAcylation is likely to occur, a scenario which was 
recently implicated as the cause of T2DM-associated erectile dysfunction, via its’ inhibition of 
nitric oxide synthetase; the enzyme responsible for eNOS formation and vasodilation [
109
].  
Moreover, a disproportionate balance of O-GlcNAc cycling enzymes has been proven to cause 
metabolic impairment in all of the tissues studied here [
41,83,93,110,111
].  Beginning in the liver, 
following a high fat meal, increased O-GlcNAcylation of PGC-1α stimulates activity of host cell 
factor C1 (HCF-1; an epigenetic cell cycle regulator), which subsequently targets and activates 
cytosolic FOXO1 [
36,65,112
].  The now active, de-phosphorylated, FOXO1 translocates to the 
nucleus where it initiates transcription for a number of genes involved in mitochondrial 
biogenesis as well as gluconeogenesis.  To summarize, in response to excess glucose in the liver, 
O-GlcNAc paradoxically facilitates hepatic glucose release, effectively triggering and 
propagating a hyperglycemic state [
36,65,112
]. 
 At the level of the pancreas, there is now an increased flux of glucose through the HBP 
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(due to hepatic O-GlcNAc induced hyperglycemia).  Consequently, the transcriptional initiation 
factors called NeuroD1 and pancreas-duodenum homeobox-1 (PDX-1) become excessively O-
GlcNAcylated leading to increased expression of the insulin gene [
93
]. These events demonstrate 
how O-GlcNAc-induced hyperglycemia also facilitates the onset of a hyperinsulinemic state as 
well.  
 Finally, just as it was seen in the pancreas, the effects of hyperglycemia within skeletal 
muscle result in elevated UDP-GlcNAc levels, and yet again this leads to excessive O-
GlcNAcylation [
83
].  As a result of O-GlcNAc’s antagonistic effect on the insulin receptor 
substrates 1 and 2 (IRS1, IRS2), signal transduction by insulin is effectively severed in skeletal 
muscle [
64
]! This marks the third and final criterion for a diabetic phenotype: hyperglycemia, 
hyperinsulinemia, and insulin resistance.  
 While the activity levels for OGA or OGT were not investigated here, their respective 
gene and protein expressions indicate a high potential for being involved in transgenerational 
glucose impairment.  This became evident upon analyzing promoter methylation patterns, which 
were demonstrated to be nearly identical between fathers and offspring, despite the fact offspring 
whose tissues were studied all consumed the same control diet (10% energy from fat).   
 Taken together, these data demonstrate that paternal nutrition and physical activity play 
an important role in shaping the glucose and energy metabolism of male progeny.  Moreover, 
these potentially transgenerational changes are the product of parent-specific epimarkers (e.g. 
DNA methylation) that alter genomic activity through successive generations.  These findings 
are well correlated to those made by Fullston et. al. (2013) discussed previously, which showed 
that paternal HFD was associated with a global reduction of DNA methylation in offspring that 
subsequently led to an impaired metabolic state [
54
].   
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 Additionally, our results suggest an alteration in lipid metabolism within different cohorts 
of offspring.  This became evident at the time they were challenged with a HFD and those 
offspring sired by exercising fathers suffered the greatest insult.  These findings were consistent 
with those made by Carone et. al. (2010), although in the current study the specific mechanisms 
that affected offspring’s susceptibility to developing impaired lipid metabolism were not 
explored [
50
]. 
 It is important to note that although elevated O-GlcNAcylation has potentially disastrous 
effects within the insulin sensitive tissues described here, it may actually have clinical benefit in 
other tissues.  For instance, high levels of O-GlcNAc in the brain serves a protective role by 
preventing hyperphosphorylation of Tau proteins, thereby inhibiting the formation of 
neurofibrillary tangles characteristic to the onset of Alzheimer’s disease [84,113].  Such 
observations inspire the possibility of using ‘O-GlcNAcylation modulation’ as a means of 
preventing cognitive decline, although at the present no such proposals could be found.  
 While further research is needed to investigate the persistence of epigenetic programming 
within the germ line (e.g. F2, F3, and so on), these data shown here offer insight into abnormal 
epigenetic profiles associated with glucose impairment.  We hope one day soon these 
observations will help contribute to the development of improved intervention techniques, as 
well as novel treatments that encompass all aspects of metabolic disease in humans.  The purpose 
of this study, however, was not only to help develop new treatments for the ongoing fight against 
obesity and type 2 diabetes – it was also to find new avenues by which these overly prevalent 
diseases could be prevented and reversed.  
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